

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## KEY DRIVERS OF INNOVATIVENESS APPRAISAL FOR MEDICINES: A CRITICAL REVIEW OF THE ITALIAN EXPERIENCE AFTER THE ADOPTION OF THE NEW RANKING SYSTEM

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041259
Article Type:	Original research
Date Submitted by the Author:	03-Jun-2020
Complete List of Authors:	Galeone, Carlotta; Statinfo , Biostatistics & Outcome Research Unit Bruzzi, Paolo; IRCCS AOU San Martino, Department of Clinical Epidemiology Jommi, Claudio; Universita Bocconi CER GAS, SDA Bocconi School of Management
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **KEY DRIVERS OF INNOVATIVENESS APPRAISAL FOR MEDICINES: A CRITICAL**  
4  
5 **REVIEW OF THE ITALIAN EXPERIENCE AFTER THE ADOPTION OF THE NEW**  
6  
7 **RANKING SYSTEM**  
8  
9  
10  
11  
12  
13

14 **Running title:** Innovativeness appraisal for medicines in Italy  
15

16  
17  
18  
19  
20 Carlotta Galeone, Paolo Bruzzi, Claudio Jommi  
21  
22  
23  
24  
25  
26

27 **Carlotta Galeone**  
28

29 Biostatistics & Outcome Research Unit  
30

31 Statinfo  
32

33 Renate (MB)  
34

35 Italy  
36  
37  
38  
39  
40  
41  
42

43 **Paolo Bruzzi**  
44

45 Department of Clinical Epidemiology  
46

47 IRCCS San Martino - IST,  
48

49 Genoa  
50

51 Italy  
52  
53  
54  
55  
56  
57

**Claudio Jommi**

Cergas (Centre for Research on Health and Social Care Management), SDA Bocconi School of Management,  
Bocconi University,  
Milan  
Italy.

**Corresponding Author:**

Carlotta Galeone, *PhD ScD*

Biostatistics & Outcome Research Unit, Statinfo

Via Concordia 6, 20838 Renate (MB)

Phone: +39 (0)3629238209

Fax: +39 (0)3629238205

carlotta.galeone@statinfo.org

**Word Count:** 2,563 words

## ABSTRACT

**Objective:** In 2017, the Italian Medicines Agency (AIFA) introduced a standardized process to appraise innovativeness of medicines. Innovative medicines are provided speedier market access and dedicated funds. Innovativeness criteria are: unmet therapeutic need, added therapeutic value and quality of the evidence (GRADE method). We investigated the role played by these three criteria on the final decision, if these criteria have been consistently used over time and if other variables have influenced decision-making.

**Design:** Critical review and data analyses of appraisal reports on innovativeness. No patients were directly involved in this study.

**Setting and Participants:** We scrutinized 54 appraisals reports available on AIFA's website (2017-2019).

**Primary and secondary outcome measures:** The impact of the three domains on final decision was investigated through a contingency table with Chi-square or Fisher's exact test, as appropriate. The consistency of the process over time was investigated through a recursive algorithm for innovativeness, using a deterministic approach.

**Results:** Among 54 appraisal reports on innovativeness available, 35 (65%) and 19 (35%) were for oncology and non-oncology medicines, respectively. The appraisals were equally distributed among "fully innovative" (35%), "conditionally innovative" (32%) and "not innovative" (33%). Added therapeutic value was the most important driver on innovativeness decision, followed by quality of the evidence. More recently appraised medicines, orphan designation, pediatric/mixed indications, and medicines approved with at least one supportive RCT were appraised 'innovative' by a larger proportion, but no statistical significance was found. The recursive algorithm shows a high level of internal consistency, accounting for 81% of appraisals.

1  
2  
3 **Conclusions:** Despite some limitations, including the moderate number of appraisals, this paper  
4 provides an insight into the determinants of innovativeness appraisals for medicines in Italy and  
5 the consistency of the appraisal process. This has important implications in terms of transparency  
6 and accountability in the prioritization process applied to innovative medicines.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### STRENGTHS AND LIMITATIONS OF THIS STUDY

- After the introduction in Italy of a new process for appraising medicines innovativeness in 2017, the drivers of innovativeness appraisal of medicines and the consistency of the relevant appraisal process were here investigated for the first time.
- The results of this study have important implications in terms of transparency and accountability in the prioritization process applied to innovative medicines.
- This study was based on a limited number of appraisals, but we systematically considered all the available ones.



## INTRODUCTION

Market Access for pharmaceuticals in Italy is managed by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA). AIFA, differently from most other European Countries medicines agencies, have both regulatory and access competences<sup>1</sup>. The latter include the negotiation of reimbursement, ex-factory price and managed entry agreements and the appraisal of innovativeness status, possibly required by the pharmaceutical companies at market launch or autonomously carried out by AIFA<sup>2</sup>. Innovativeness status has some advantages from an access perspective, including two dedicated funds (one for cancer medicines and the other for non-cancer medicines) and immediate access to regional markets.

The criteria to get innovativeness status, which can be attributed only to drugs indicated for serious illnesses (*life-threatening diseases; diseases producing frequent hospitalizations or causing disabilities that can seriously compromise quality of life*) are the unmet therapeutic need, the added therapeutic value and the quality of the evidence (Determina AIFA 519/2017)<sup>3</sup>.

The **unmet therapeutic need** is rated as:

- *Maximum*: there are no alternatives for that specific indication;
- *Important*: there are a few alternatives, but with no impact on clinically relevant endpoints;
- *Moderate*: there are alternatives with a limited and/or uncertain or unreliable impact on clinically relevant endpoints;
- *Poor*: there are alternatives for the same indication with clinically proven reliable results;
- *Absent*: there are alternatives for the same indication with an important impact on the natural history of the disease.

The added **therapeutic value**, that refers to clinical benefit, can be rated as:

- 1  
2  
3 • *Maximum*: the new drug has proven larger efficacy than any possible existing  
4 alternatives. In this case, the treatment is able to either cure the illness or significantly  
5 alter its natural history;  
6  
7
- 8  
9  
10 • *Important*: the new drug has a proven larger efficacy measured on clinically relevant  
11 endpoints, decreases the risk of invalidating or fatal complications, avoids highly  
12 dangerous clinical procedures or has more favorable risk/benefit (R/B) ratio than any  
13 available alternatives. In a subset of patients, the treatment either modifies the natural  
14 history of the disease or is beneficial in other clinically significant ways, e.g. in terms of  
15 quality of life or disease-free intervals, when compared to available alternatives;  
16  
17
- 18 • *Moderate*: the new drug has a larger efficacy than any available alternatives, but it is only  
19 moderate or only proven in some subsets of patients, with limited impact on the quality of  
20 life;  
21  
22
- 23 • *Poor*: the new drug has either a limited improvement of efficacy or has been proven on  
24 endpoints which are not clinically relevant. Minor advantages, e.g. more acceptable  
25 administration route;  
26  
27
- 28 • *Absent*: the new drug has no relevant benefit when compared to other available  
29 treatments.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Endpoints relevance has been specified for cancer medicines, being overall survival (OS)  
43 considered the gold standard, and the lack of OS data needed to justify. The document quotes  
44 that progression-free survival (PFS), disease-free survival (DFS), full response time or other  
45 surrogated endpoints (with already established clinical benefits) may be taken into account,  
46 according to indication and settings. Toxicity is also considered to evaluate the treatment's  
47 adequacy.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 To appraise the **quality of evidence**, AIFA has chosen the Grading of Recommendations  
4 Assessment, Development and Evaluation (GRADE) method<sup>4</sup>. According to this approach, the  
5 quality of clinical evidence can be graded as high, moderate, low or very low. The choice of  
6 GRADE methodology was aimed at improving the transparency and reproducibility of the  
7 appraisal process; this structured and flexible methodological tool provides a systematic  
8 approach in the assessment and is meant to minimize biases and improve consistency of the  
9 decisions<sup>5</sup>.

10  
11 The innovativeness is appraised per indication, and the innovativeness status lasts three years.  
12 The appraisal model represents a common framework for all indications, even if safeguard  
13 clauses are provided for rare indications where the quality of the evidence is more likely to be  
14 lower.

15  
16 The industry usually applies for innovativeness, even if AIFA can proceed to evaluate it  
17 regardless of the industry' application. The innovativeness request is appraised by the AIFA's  
18 Technical-Scientific Committee (CTS). CTS may decide for full innovativeness, conditional  
19 innovativeness or non-innovative. Conditionally innovative medicines share with fully  
20 innovative medicines only the immediate access to regional markets. Conditional innovativeness  
21 is granted when the evidence is not sufficiently mature to provide a full innovativeness status and  
22 lasts 18 months.

23  
24 Innovativeness may be granted, if both unmet need and added therapeutic value are graded  
25 "Maximum" or "Important" and the quality of evidence is rated "High". Conversely, if the unmet  
26 need or the added therapeutic value are graded "Poor" or "Absent", or the quality of evidence is  
27 rated "Low" or "Very Low" innovativeness will be not granted. For rare indications the

1  
2  
3 innovative status may be granted even if the quality of evidence is graded “Low”, but the unmet  
4 need and the added therapeutic value are both at least “Important” (Figure 1).  
5

6  
7  
8 Pharmaceutical companies are informed by AIFA on the intended final appraisal and can rebut  
9  
10 on appraisals in ten days. The final appraisal is published on the AIFA’s website, together with a  
11 short description of the rationale behind the decision taken (www.aifa.gov.it).  
12  
13

14  
15 Despite the growing interest in this new criteria and the relevant appraisal process<sup>6</sup>, there is no  
16 evidence on the role played by the three criteria on the final decision, if these criteria have been  
17 consistently used overtime and if other variables do influence the innovativeness status.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

Appraisal reports on innovativeness were downloaded from the AIFA's website<sup>7</sup> as at 31 December 2019: 54 appraisal reports were found, 35 and 19 for oncology and non-oncology medicines respectively.

The following data were retrieved from the appraisal reports and inserted into an extraction template:

- final appraisal (“fully innovative”, “conditionally innovative” or “not innovative”);
- rank attributed to the unmet need, the added therapeutic value and the quality of evidence;
- variables that may have an influence on the final decision taken by the CTS, including:
  - the target disease: oncological (solid/hematological) disease or non-oncological disease (infectious/autoimmune/other diseases);
  - population: adult, pediatric, mixed;
  - orphan drug designation by EMA (European Medicines Agency): yes or no;
  - number of “Summaries of Findings” (SoF) according to the GRADE system that reported the key information concerning the magnitudes of relative and absolute effects of the interventions examined, the amount of available evidence and the certainty (or quality) of available evidence<sup>8</sup>;
  - number of clinical studies considered;
  - number of randomized clinical trials (RCT), supporting the application for innovativeness;
  - number of observational studies, supporting the application for innovativeness;
- appraisal date.

1  
2  
3 We firstly calculated some descriptive statistics: frequencies and percentages for categorical  
4 variables; mean and median values, standard deviations (SD), quartiles and extreme values for  
5 continuous variables.  
6  
7

8  
9  
10 Afterwards, we scrutinized the role played by the above-mentioned variables on the  
11 innovativeness appraisal. Fully innovative and conditionally innovative appraisals were merged,  
12 given the limited number of appraisal reports. Categorical data were analyzed using a  
13 contingency table with the Chi-square or Fisher's exact test, as appropriate. Continuous data  
14 were analyzed using a Student's T-test, after checking for normal distribution (based on the  
15 Shapiro-Wilk statistic), or a Wilcoxon rank-sum test otherwise.  
16  
17

18  
19 Finally, we developed a recursive algorithm for innovativeness, using a determinist approach, to  
20 scrutinize the role played by the three above-mentioned criteria (unmet need, therapeutic added  
21 value, quality of the evidence).  
22  
23

### 24 **Patient and Public Involvement**

25  
26 No patients were directly involved in this study.  
27  
28  
29  
30  
31  
32

## RESULTS

Figure 2 shows that appraisals were equally distributed among “fully innovative” (35% of the total), “conditionally innovative” (32%) and “not innovative” (33%).

Cancer medicines were more often appraised as potentially innovative, whereas other drugs show a higher proportion of non-innovative status (29% cancer drugs were appraised not innovative, compared to 42% non-cancer treatments), but the difference was not significant ( $p=0.42$ ).

The role played on innovativeness status by the appraisal year, orphan designation, target disease, target population, number of Summary of Findings, overall number of studies, number of RCT and Phase I/II studies are illustrated in Table 1.

**Table 1.** Variables detected on the appraisal document and innovativeness status (2017-2019).

	ALL DISEASES (n=53 <sup>a</sup> )				ONCOLOGY (n=34 <sup>a</sup> )				NON-ONCOLOGY (n=19)			
	<i>All medicines</i>	<i>Innovative<sup>b</sup></i>	<i>Not innovative</i>	<i>p-value</i>	<i>All medicines</i>	<i>Innovative<sup>b</sup></i>	<i>Not Innovative</i>	<i>p-value</i>	<i>All medicines</i>	<i>Innovative<sup>b</sup></i>	<i>Not Innovative</i>	<i>p-value</i>
<b>CTS appraisal year</b>	n (%)	n (%)	n (%)		n (%)	n (%)	n (%)		n (%)	n (%)	n (%)	
2017	27 (50.9)	17 (63.0)	10 (37.0)		17 (50.0)	11 (64.7)	6 (35.3)		10 (52.6)	6 (60.0)	4 (40.0)	
2018	21 (39.6)	14 (66.7)	7 (33.3)		13 (38.2)	9 (69.2)	4 (30.8)		8 (42.1)	5 (62.5)	3 (37.5)	
2019	5 (9.4)	4 (80.0)	1 (20.0)	0.76	4 (11.8)	4 (100.0)	0 (0.0)	0.38	1 (5.3)	0 (0.0)	1 (100.0)	0.48
<b>Orphan designation</b>												
No	18 (33.9)	10 (55.5)	8 (44.5)		11 (32.3)	8 (72.7)	3 (27.3)		8 (42.1)	3 (37.5)	5 (62.5)	
Yes	35 (66.1)	25 (71.4)	10 (28.6)	0.25	23 (67.7)	16 (69.6)	7 (30.4)	0.98	11 (57.9)	8 (72.7)	3 (27.3)	0.18
<b>Disease</b>												
Solid tumours	19 (35.8)	14 (73.7)	5 (26.3)		19 (55.9)	14 (73.7)	5 (26.3)		-	-	-	
Hematological malignancies	15 (28.3)	10 (66.7)	5 (33.3)		15 (44.1)	10 (66.7)	5 (33.3)	0.97	-	-	-	
Infectious diseases	5 (9.4)	3 (60.0)	2 (40.0)		-	-	-		5 (26.3)	3 (60.0)	2 (40.0)	
Autoimmune diseases	2 (3.8)	0 (0)	2 (100.0)		-	-	-		2 (10.5)	0 (0.0)	2 (100.0)	



1													
2													
3	Other	12 (22.7)	8 (66.7)	4 (33.3)	0.33	-	-	-		12 (63.2)	8 (66.7)	4 (33.3)	0.21
4													
5	<b>Population</b>												
6													
7													
8	Adults only	45 (84.9)	29 (64.4)	16 (35.6)		31 (91.2)	22 (71.0)	9 (29.0)		14 (73.7)	7 (50.0)	7 (50.0)	
9													
10	Pediatric or mixed	8 (15.1)	6 (75.0)	2 (25.0)	0.70	3 (8.8)	2 (66.7)	1 (33.3)	0.99	5 (26.3)	4 (80.0)	1 (20.0)	0.34
11													
12	<b>Mean number SoF (SD)</b>	3.6 (3.3)	3.4 (2.9)	4.1 (4.0)	0.88	2.7 (2.5)	2.8 (2.6)	2.6 (2.5)	0.43	5.3 (3.9)	4.8 (3.2)	5.9 (4.9)	0.80
13													
14													
15	<b>N studies</b>												
16													
17	1	41 (77.4)	27 (65.8)	14 (34.1)		31 (91.2)	21 (67.7)	10 (32.3)		10 (52.6)	6 (60.0)	4 (40.0)	
18													
19	>1	12 (22.6)	8 (66.7)	4 (33.3)	0.99	3 (8.8)	3 (100.0)	0 (0.0)	0.54	9 (47.4)	5 (55.6)	4 (44.4)	0.99
20													
21													
22	<b>N RCT</b>												
23													
24	0	12 (22.6)	7 (58.3)	5 (41.7)		11 (32.3)	6 (54.5)	5 (45.5)		1 (5.3)	1 (100.0)	0 (0.0)	
25													
26	1	31 (58.5)	22 (71.0)	9 (29.0)		21 (61.8)	16 (76.2)	5 (23.8)		10 (52.6)	6 (60.0)	4 (40.0)	
27													
28	>1	10 (18.9)	6 (60.0)	4 (40.0)	0.66	2 (5.9)	2 (100.0)	0 (0.0)	0.28	8 (42.1)	4 (50.0)	4 (50.0)	0.62
29													
30													
31	<b>N clinical trials phase I/II</b>												
32													
33	0	39 (73.6)	26 (66.7)	13 (33.3)		23 (67.6)	18 (78.3)	5 (21.7)		16 (84.2)	8 (50.0)	8 (50.0)	
34													
35	≥1	14 (26.4)	9 (64.3)	5 (35.7)	0.99	11 (32.4)	6 (54.5)	5 (45.5)	0.23	3 (15.8)	3 (100.0)	0 (0.0)	0.23
36													
37													
38													

1  
2  
3 <sup>a</sup>For one cancer drug (daratumumab) one appraisal was duplicated (innovativeness status was confirmed). For this reason, only one evaluation was  
4 considered in the present analysis.  
5  
6

7  
8 <sup>b</sup>Innovative status includes fully and conditionally innovative.  
9  
10

11 CTS: Technical-scientific committee; SoF: Summaries of Findings; RCT: Randomized Clinical Trial.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

1  
2  
3 More recently assessed medicines, orphan drugs, pediatric/mixed indications, and medicines  
4 approved with at least one RCT were appraised innovative by a larger proportion. However,  
5  
6 none of these variables has a significant impact from a statistical viewpoint. In oncological  
7  
8 setting, innovative drugs provided on average more RCT evidence in support of the application  
9  
10 when compared to non-oncological ones. Furthermore, rarity (according to the orphan drug  
11  
12 definition), and type of disease did not seem to be determinant for the innovativeness evaluation.  
13  
14 Similarly, in the non-oncological setting, no significant differences were found in basic  
15  
16 properties between innovative and not innovative indications. Non-oncological forms have a  
17  
18 higher number of RCT supporting them compared to oncological ones (more than 1 RCT  
19  
20 supporting 42% of non-oncological ones compared to approximately 6% of oncological ones).  
21  
22  
23  
24 As a second step, we investigated the role of each of the three domains on appraisals. Table 2  
25  
26 shows the association between unmet therapeutic need, added therapeutic need and quality of  
27  
28 evidence and the final appraisal.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** Role played by the three domains on innovativeness status (2017-2019).

	<i>All medicines</i>	<i>Innovative</i>	<i>Not innovative</i>	<i>p-value</i>
<b>Unmet therapeutic need</b>				
N <sup>a</sup>	53	35	18	
Maximum (Scale=1)	8 (15.1%)	5 (62.5%)	3 (37.5%)	
Important (Scale=2)	23 (43.4%)	16 (69.6%)	7 (30.4%)	
Moderate (Scale=3)	19 (35.8%)	14 (73.7%)	5 (26.3%)	
Poor (Scale=4)	3 (5.7%)	0 (0.0%)	3 (100.0%)	0.09
Range	1 - 4	1 - 3	1 - 4	
Mean (SD)	2.3 (0.8)	2.3 (0.7)	2.4 (1.0)	0.57
Median (Range IQ)	2 (2-3)	2 (2-3)	2 (2-3)	
<b>Added therapeutic value</b>				
N <sup>a</sup>	52 <sup>b</sup>	35	17 <sup>b</sup>	
Maximum (Scale=1)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Important (Scale=2)	18 (34.6%)	16 (88.9%)	2 (11.1%)	
Moderate (Scale=3)	22 (42.3%)	19 (86.4%)	3 (13.6%)	
Poor (Scale=4)	12 (23.1%)	0 (0.0%)	12 (100.0%)	<0.01
Range	2 - 4	2 - 3	2 - 4	

Mean (SD)	2.9 (0.8)	2.5 (0.5)	3.6 (0.7)	<0.01
Median (Range IQ)	3 (2-3)	3 (2-3)	4 (3-4)	

### Quality of clinical evidence

#### (GRADE evaluation)

N <sup>a</sup>	53	35	18	
High (Scale=1)	7 (13.2%)	6 (85.7%)	1 (14.3%)	
Moderate (Scale=2)	26 (49.1%)	20 (76.9%)	6 (23.1%)	
Low (Scale=3)	16 (30.2%)	9 (56.2%)	7 (43.8%)	
Very low (Scale=4)	4 (7.5%)	0 (0.0%)	4 (100.0%)	0.01
Range	1 - 4	1 - 3	1 - 4	
Mean (SD)	2.3 (0.8)	2.1 (0.7)	2.8 (0.9)	<0.01
Median (Range IQ)	2 (2-3)	2 (2-3)	3 (2-3)	

IQ: interquartile; SD: standard deviation

<sup>a</sup> One evaluation was duplicate for innovativeness time extension (#12 and #42-Daratumumab).

For this reason, only one evaluation was considered in the present analyses.

<sup>b</sup> For one rating (#10-Nivolumab), the added therapeutic value was reported as “not assessable”.

1  
2  
3 A significant difference between innovative and not innovative outcomes was found both for the  
4 added therapeutic value and the quality of evidence domains ( $p < 0.01$ ). For innovative and non-  
5 innovative indications, the added therapeutic value had an average score of 2.5 (between  
6 “Moderate” and “Important”) and 3.6 (between “Poor” and “Moderate”) respectively. The  
7 quality of evidence for innovative and non-innovative medicines had an average score of 2.1  
8 (“Moderate”), and 2.8 (between “Low” and “Moderate”) respectively.  
9

10  
11  
12 The average scores of unmet need for innovative and not innovative evaluations were quite  
13 similar.  
14

15 Taking into account the above-mentioned findings, we developed a decision tree using a  
16 deterministic approach (Figure 3).  
17

18  
19 The flowchart illustrated by Figure 3 confirms that added therapeutic value was the most  
20 influential parameter, followed by GRADE evaluation, whereas the unmet therapeutic need had a  
21 quite limited impact on the final appraisal. When the added therapeutic value was rated as "poor"  
22 or "absent", or when the GRADE evaluation was "very low", the indication is never considered  
23 innovative. Innovativeness resulted from an at least a "moderate" added therapeutic value  
24 combined with an at least a "moderate" GRADE evaluation.  
25

26  
27 The decision tree accounted for 43 out of 53 cases (81%). As for the other 10 appraisals, six of  
28 them were either "conditionally innovative" or "not innovative" because they had "moderate"  
29 added therapeutic value and a "low" GRADE evaluation. The other four cases were given either  
30 a "full" or a "conditioned" innovativeness because they had a "moderate" added therapeutic value  
31 along with a "high" GRADE evaluation. When the final assessment was uncertain, it was not  
32 possible to discern factors determining the final appraisal, nor to find out the driver from the  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

characteristics of the indication, such as the disease (oncological or non-oncological) or the rarity of the disease.

For peer review only

## DISCUSSION

The present study analyzed the new AIFA approach to appraise innovativeness for medicines. The appraisal process relies on three criteria: unmet therapeutic need, added therapeutic value, and quality of clinical evidence assessed with GRADE method. Despite the growing interest in this new appraisal process, there is still no evidence on the role played by the three criteria on the final decision, if these criteria have been consistently used overtime and if other variables do influence the innovativeness status. We found that added therapeutic value was the most influential parameter, followed by quality of evidence, whereas unmet therapeutic need had a quite limited impact on the final appraisal. It seems that a high unmet therapeutic need is perceived as a prerequisite of innovativeness, instead of being the driver of the appraisal process. We investigated the potential role of other variables – namely the characteristics of the drugs and the evidence provided – that is whether there is a systematic correlation between these variables and innovativeness status. Some relationships were found: for examples, a larger proportion of orphan drugs were appraised innovative. However, the statistical significance of these relationships is low. We have also investigated the consistency of the appraisal process. Despite the high level of discretion left to the Scientific Committee in appraising the unmet need and the added therapeutic value, this process looked intrinsically coherent. Other countries have relied on a formal appraisal of added therapeutic value. This is done for example in France and Germany where all new drugs and indications are appraised and added therapeutic value is ranked in five and six levels respectively<sup>1</sup>. Ranks are used for price / discount negotiations. In France the absolute benefit is ranked too and used to take decisions on reimbursement (introduction in the positive list and co-payment). There is evidence on the (i) coherence between ranks attributed in the two countries to the same medicine<sup>9</sup>, consistency



1  
2  
3 between these rankings and other way of measuring added value by HTA organisations (e.g.  
4  
5 between the added therapeutic value rank in France and QALYs – Quality Adjusted Life Years  
6  
7 gained - in England<sup>10</sup>) and scientific societies<sup>11</sup> and the role played by the added therapeutic  
8  
9 value in price/discount negotiation<sup>12</sup>. Italy is the only country in Europe where (i) innovativeness  
10  
11 status is appraised on the grounds of a ranked unmet need, added therapeutic value and quality of  
12  
13 the evidence, (ii) innovative medicines are provided a speeder market access and dedicated funds  
14  
15 and (iii) added therapeutic value rank is not used in price negotiation. As a consequence, our  
16  
17 results, besides being the first one published on the Italian-case, cannot be fully compared with  
18  
19 that of our countries.  
20  
21  
22

23  
24 The study has some limitations. Firstly, it is based on a quite small number of appraisals (n =  
25  
26 54). As already mentioned, innovativeness appraisals can be requested by the companies or  
27  
28 spontaneously carried out by AIFA. The information on the applicant was not available and no  
29  
30 stratified analysis could be performed, despite it would have been very interesting. We could  
31  
32 analyze only the final appraisal published by AIFA, but we did not have any access to the  
33  
34 applications submitted by the companies. This implies that the results of the present study cannot  
35  
36 be considered a predictor of the response by AIFA to the applicant. However, our analysis was  
37  
38 aimed at evaluation of the key drivers and the consistency of the AIFA decision-making process,  
39  
40 rather than the comparison of applications submitted by the companies and final decision of  
41  
42  
43  
44  
45 AIFA.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## CONCLUSIONS

Despite the above-mentioned limitations, our analysis has some important implications.

Companies are pushed to provide solutions with an added therapeutic value and a high quality of evidence, since the latter are the driver of innovativeness, which brings important advantages for market access. We are aware that investments by the pharmaceutical companies are taken globally, but the more HTA agencies insist on clear and transparent criteria to appraise new medicines, the higher will be the impact on the management of pipelines by the pharmaceutical companies.

The new process implemented by AIFA has also the advantage of enhancing transparency, accountability and, because of its intrinsic consistency, predictability of innovativeness appraisals, thus making access in Italy more reliable in this respect.

Last but not least, prioritization of access through innovativeness is managed transparently, on the grounds of quite objective criteria and providing the whole stakeholders with the rationale of decision taken.

The process could be further enhanced, for example including in a more structured framework patients reported outcome measures, whereas at present the appraisal process mostly relies on clinical variables, and proving for an interaction between innovativeness (and its domains) appraisals and price negotiation. Furthermore, future appraisals may confirm or disconfirm the pathway we have traced from the evidence collected.

However, the new innovativeness appraisal system can be considered an important step towards a more transparent and evidence-based management of access to medicines in Italy.

1  
2  
3 **Contributors:** CG, PB and CJ designed the study and developed the methods. CG and PB  
4 reviewed the literature. CG, PB and CJ contributed to the data analysis and interpretation. CG  
5 prepared the tables. CG and CJ drafted the manuscript. PB provided critical review of the  
6 manuscript. All authors have reviewed and approved the final version of the manuscript for  
7 publication.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

18 **Competing interests:** This research was partially funded by a grant from Celgene to Statinfo.  
19 CG is a senior consultant at Statinfo. CJ and PB have received a consultant fee from Celgene as  
20 scientific consultants for the project. Celgene was not involved in the preparation, drafting or  
21 editing of this manuscript.  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 **Data Statement:** Data are available in a public, open access repository. Appraisal reports on  
32 innovativeness are publicly downloadable from the AIFA's website at  
33 <https://www.aifa.gov.it/farmaci-innovativi>.  
34  
35  
36  
37  
38  
39  
40

41 **Funding:** This research was partially funded by a grant from Celgene to Statinfo.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **REFERENCES**  
4  
5

- 6 1. Panteli D, Arickx F, Cleemput I, et al. Pharmaceutical regulation in 15 European countries  
7 review. *Heal Syst Transit*. 2016;18(5):1-122.  
8  
9
- 10 2. Jommi C, Minghetti P. Pharmaceutical Pricing Policies in Italy. In: Babar Z-U-D, ed.  
11 *Pharmaceutical Prices in the 21st Century*. London: Springer; 2015:131-151.  
12  
13
- 14 3. AIFA. Criteri per la classificazione dei farmaci innovativi e dei farmaci oncologici  
15 innovativi ai sensi dell'articolo 1, comma 402, della legge 11 dicembre 2016, n. 232.  
16 2017:519. <https://www.gazzettaufficiale.it/eli/id/2017/04/05/17A02486/sg>.  
17  
18  
19  
20  
21  
22
- 23 4. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of  
24 recommendations. *BMJ*. 2004;328(7454):1490. doi:10.1136/bmj.328.7454.1490  
25  
26  
27  
28
- 29 5. Fortinguerra F, Tafuri G, Trotta F, Addis A. Using GRADE methodology to assess  
30 innovation of new medicinal products in Italy. *Br J Clin Pharmacol*. 2019;86(1):93-105.  
31 doi:10.1111/bcp.14138  
32  
33  
34  
35  
36
- 37 6. Scavone C, Capuano A, Rossi F. New criteria of Italian Medicine Agency for the  
38 attribution of therapeutic innovation: viewpoint of the pharmacologist. *G Ital di Farm e*  
39 *Farm*. 2017;9(3):5-12.  
40  
41  
42  
43
- 44 7. Agenzia Italiana del Farmaco. Farmaci innovativi. [https://www.aifa.gov.it/farmaci-](https://www.aifa.gov.it/farmaci-innovativi)  
45 [innovativi](https://www.aifa.gov.it/farmaci-innovativi). Accessed January 7, 2020.  
46  
47  
48  
49
- 50 8. The GRADE Working Group. *GRADE Handbook. Handbook for Grading the Quality of*  
51 *Evidence and the Strength of Recommendations Using the GRADE Approach*.  
52 (Schünemann H, Brożek J, Guyatt G, Oxman A, eds.); 2013.  
53  
54  
55  
56  
57

- 1  
2  
3 <https://gdt.gradeopro.org/app/handbook/handbook.html>. Accessed March 20, 2010.  
4  
5  
6 9. Ruof J, Schwartz FW, Schulenburg J-M, Dintsios C-M. Early benefit assessment (EBA) in  
7  
8 Germany: analysing decisions 18 months after introducing the new AMNOG legislation.  
9  
10 *Eur J Heal Econ*. 2014;15(6):577-589.  
11  
12  
13 10. Drummond M, de Pouvourville G, Jones E, Haig J, Saba G, Cawston H. A comparative  
14  
15 analysis of two contrasting European approaches for rewarding the value added by drugs  
16  
17 for cancer: England versus France. *Pharmacoeconomics*. 2014;32(5):509-520.  
18  
19  
20 11. Li J, Vivot A, Alter L, Durand-Zaleski I. Appraisal of cancer drugs: a comparison of the  
21  
22 French health technology assessment with value frameworks of two oncology societies.  
23  
24 *Expert Rev Pharmacoecon Outcomes Res*. 2019;26:1-5.  
25  
26  
27 12. Theidel U, von der Schulenburg JMG. Benefit assessment in Germany: implications for  
28  
29 price discounts. *Health Econ Rev*. 2016;6(33):1-12. doi:10.1186/s13561-016-0109-3  
30  
31  
32  
33 13. Di Marzio S. E l'AIFA tracciò la strada dell'innovatività. *AboutPharma*. 2017;148:28-30.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Criteria used to evaluate innovativeness adopted by Italian Medicines Agency.

Adapted from Recchia, 2017 13

\* For rare disease there is the following exception: the fully innovative is attributed in the presence of at least important unmet therapeutic need and added therapeutic value in presence of at least low quality of clinical evidence.

170x108mm (144 x 144 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Innovative appraisals by the Italian Medicines Agency (2017-2019).

155x117mm (144 x 144 DPI)




Figure 3. Deterministic decision tree based on the available appraisals (2017-2019).

#Nr. Indicate the drug innovativeness evaluation form available on the AIFA website

Onco: Oncology  
 Hema: Hematology  
 RD: rare disease  
 OBS: Observational study  
 RCT: Randomized Clinical Trial

217x130mm (300 x 300 DPI)



# BMJ Open

## KEY DRIVERS OF INNOVATIVENESS APPRAISAL FOR MEDICINES: THE ITALIAN EXPERIENCE AFTER THE ADOPTION OF THE NEW RANKING SYSTEM

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041259.R1
Article Type:	Original research
Date Submitted by the Author:	15-Sep-2020
Complete List of Authors:	Galeone, Carlotta; Università degli Studi di Milano-Bicocca, Bicocca Applied Statistics Center (B-ASC) Bruzzi, Paolo; IRCCS AOU San Martino, Department of Clinical Epidemiology Jommi, Claudio; Università Bocconi CERGAS, SDA Bocconi School of Management
<b>Primary Subject Heading</b>:	Health policy
Secondary Subject Heading:	Public health
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **KEY DRIVERS OF INNOVATIVENESS APPRAISAL FOR MEDICINES: THE**  
4  
5 **ITALIAN EXPERIENCE AFTER THE ADOPTION OF THE NEW RANKING SYSTEM**  
6  
7  
8  
9

10  
11 **Running title:** Innovativeness appraisal for medicines in Italy  
12  
13

14  
15  
16  
17 Carlotta Galeone, Paolo Bruzzi, Claudio Jommi  
18  
19  
20  
21  
22  
23  
24

25 **Carlotta Galeone**

26  
27 Bicocca Applied Statistics Center (B-ASC)

28  
29 University of Milano-Bicocca

30  
31 Milan

32  
33 Italy  
34  
35  
36  
37  
38  
39  
40

41 **Paolo Bruzzi**

42  
43 Department of Clinical Epidemiology

44  
45 IRCCS San Martino - IST,

46  
47 Genoa

48  
49 Italy  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Claudio Jommi**

Cergas (Centre for Research on Health and Social Care Management), SDA Bocconi School of Management,  
Bocconi University,  
Milan  
Italy.

**Corresponding Author:**

Carlotta Galeone, *PhD ScD*

Biostatistics & Outcome Research Unit, Statinfo

Via Concordia 6, 20838 Renate (MB)

Phone: +39 (0)3629238209

Fax: +39 (0)3629238205

carlotta.galeone@statinfo.org

**Word Count:** 2,938 words

## ABSTRACT

**Objective:** In 2017, the Italian Medicines Agency (AIFA) introduced a standardized process to appraise innovativeness of medicines. Innovative medicines are provided speedier market access and dedicated funds. Innovativeness criteria are: unmet therapeutic need, added therapeutic value and quality of the evidence (GRADE method). We investigated the role played by these three criteria on the final decision aimed to understand how the new Italian innovativeness appraisal framework was implemented.

**Design:** A desk research gathered AIFA's appraisals reports on innovativeness and data analyses were conducted. No patients were directly involved in this study.

**Setting and Participants:** We scrutinized all 77 appraisals reports available on AIFA's website (2017-2020).

**Primary and secondary outcome measures:** The impact of the three domains on final decision was investigated through a series of univariate analyses. A recursive algorithm for innovativeness using a determinist approach (merely data-driven) to scrutinize the role played by the three domains was performed.

**Results:** Among 77 appraisal reports on innovativeness available, 49 (64%) and 28 (36%) were for oncology and non-oncology medicines, respectively. The appraisals were equally distributed among "fully innovative" (36%), "conditionally innovative" (30%) and "not innovative" (34%). Added therapeutic value was the most important driver on innovativeness decision, followed by quality of the evidence. Drugs for rare diseases and with pediatric/mixed indications were appraised 'innovative' by a larger proportion, but no statistical significance was found. The recursive algorithm shows a good descriptive accuracy, accounting for 82% of appraisals.

1  
2  
3 **Conclusions:** Despite some limitations, including the moderate number of appraisals, this paper  
4 provides an insight into the determinants of innovativeness appraisals for medicines in Italy and  
5 the accuracy of the appraisal process. This has important implications in terms of transparency  
6 and accountability in the prioritization process applied to innovative medicines.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- This is an original, up to date analysis of the new National Drugs Agency appraisals framework for drug innovativeness in the Italian setting
- This study was based on a limited number of appraisals, but we systematically considered all the available ones
- The relatively small number of appraisals did not allow to analyze possible different patterns of association between the three innovativeness criteria and the type of innovativeness (i.e., fully or conditionally innovative)

## INTRODUCTION

Market Access for pharmaceuticals in Italy is managed by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA). AIFA, differently from most other European Countries medicines agencies, have both regulatory and access competences.[1] The latter include the negotiation of reimbursement, ex-factory price and managed entry agreements and the appraisal of innovativeness status, possibly required by the pharmaceutical companies at market launch or autonomously carried out by AIFA.[2] Innovativeness status has some advantages from an access perspective, including two dedicated funds (one for cancer medicines and the other for non-cancer medicines) and immediate access to regional markets.

The criteria to get innovativeness status, which can be attributed only to drugs indicated for serious illnesses (*life-threatening diseases; diseases producing frequent hospitalizations or causing disabilities that can seriously compromise quality of life*) are the unmet therapeutic need, the added therapeutic value and the quality of the evidence (Determina AIFA 519/2017).[3]

The **unmet therapeutic need** is rated as:

- *Maximum*: there are no alternatives for that specific indication;
- *Important*: there are a few alternatives, but with no impact on clinically relevant endpoints;
- *Moderate*: there are alternatives with a limited and/or uncertain or unreliable impact on clinically relevant endpoints;
- *Poor*: there are alternatives for the same indication with clinically proven reliable results;
- *Absent*: there are alternatives for the same indication with an important impact on the natural history of the disease.



The added **therapeutic value**, that refers to clinical benefit, can be rated as:

- *Maximum*: the new drug has proven larger efficacy than any possible existing alternatives. In this case, the treatment is able to either cure the illness or significantly alter its natural history;
- *Important*: the new drug has a proven larger efficacy measured on clinically relevant endpoints, decreases the risk of invalidating or fatal complications, avoids highly dangerous clinical procedures or has more favorable risk/benefit (R/B) ratio than any available alternatives. In a subset of patients, the treatment either modifies the natural history of the disease or is beneficial in other clinically significant ways, e.g. in terms of quality of life or disease-free intervals, when compared to available alternatives;
- *Moderate*: the new drug has a larger efficacy than any available alternatives, but it is only moderate or only proven in some subsets of patients, with limited impact on the quality of life;
- *Poor*: the new drug has either a limited improvement of efficacy or has been proven on endpoints which are not clinically relevant. Minor advantages, e.g. more acceptable administration route;
- *Absent*: the new drug has no relevant benefit when compared to other available treatments.

Endpoints relevance has been specified for cancer medicines, being overall survival (OS) considered the gold standard, and the lack of OS data needed to justify. The document quotes that progression-free survival (PFS), disease-free survival (DFS), full response time or other surrogated endpoints (with already established clinical benefits) may be taken into account,

1  
2  
3 according to indication and settings. Toxicity is also considered to evaluate the treatment's  
4  
5 adequacy.  
6

7  
8 To appraise the **quality of evidence**, AIFA has chosen the Grading of Recommendations  
9  
10 Assessment, Development and Evaluation (GRADE) method.[4] According to this approach, the  
11  
12 quality of clinical evidence can be graded as high, moderate, low or very low. The choice of  
13  
14 GRADE methodology was aimed at improving the transparency and reproducibility of the  
15  
16 appraisal process; this structured and flexible methodological tool provides a systematic  
17  
18 approach in the assessment and is meant to minimize biases and improve consistency of the  
19  
20 decisions.[5]  
21  
22

23  
24 The innovativeness is appraised per indication, and the innovativeness status lasts three years.  
25  
26 The appraisal model represents a common framework for all indications, even if safeguard  
27  
28 clauses are provided for rare indications where the quality of the evidence is more likely to be  
29  
30 lower.  
31  
32

33  
34 The industry usually applies for innovativeness, even if AIFA can proceed to evaluate it  
35  
36 regardless of the industry' application. The innovativeness request is appraised by the AIFA's  
37  
38 Technical-Scientific Committee (CTS). CTS may decide for full innovativeness, conditional  
39  
40 innovativeness or non-innovative. Conditionally innovative medicines share with fully  
41  
42 innovative medicines only the immediate access to regional markets. Conditional innovativeness  
43  
44 is granted when the evidence is not sufficiently mature to provide a full innovativeness status and  
45  
46 lasts 18 months.  
47  
48

49  
50 The new decision rule adopted by AIFA (Figure 1)[6] consists to grant innovativeness if both  
51  
52 unmet need and added therapeutic value are graded "Maximum" or "Important" and the quality  
53  
54 of evidence is rated "High" (green zone). Conversely, if the unmet need or the added therapeutic  
55  
56  
57

1  
2  
3 value are graded “Poor” or “Absent”, or the quality of evidence is rated “Low” or “Very Low”  
4  
5 innovativeness will be not granted (red zone). For rare indications, the innovative status may be  
6  
7 granted even if the quality of evidence is graded “Low”, but the unmet need and the added  
8  
9 therapeutic value are both at least “Important”. To note, in the intermediate situations (grey zone)  
10  
11 there is uncertainty about innovation status, and AIFA decides case-by-case.  
12  
13

14  
15 Pharmaceutical companies are informed by AIFA on the intended final appraisal and can rebut  
16  
17 on appraisals in ten days. The final appraisal is published on the AIFA’s website, together with a  
18  
19 short description of the rationale behind the decision taken ([www.aifa.gov.it](http://www.aifa.gov.it)).  
20

21  
22 Despite the growing interest in this new criteria and the relevant appraisal process,[7] to our  
23  
24 knowledge only preliminary descriptive analyses (based on less of 20 innovativeness appraisals  
25  
26 updated to 2018) were available[8–10] and no clear and robust evidence emerged on the role  
27  
28 played by the three criteria on the final decision, if these criteria have been consistently used  
29  
30 over time and if other variables influence the innovativeness status.  
31  
32

33  
34 Our analyses, based on available innovativeness appraisals updated to July 2020, aim to cover  
35  
36 these information gaps and, more in general, to understand how the new Italian innovativeness  
37  
38 appraisal framework was implemented.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

Appraisal reports on innovativeness were downloaded from the AIFA's website[11] as at 31 July 2020: 77 appraisal reports were found, 49 and 28 for oncology and non-oncology medicines respectively.

The following data were retrieved from the appraisal reports and inserted into an extraction template:

- final appraisal (“fully innovative”, “conditionally innovative” or “not innovative”);
- rank attributed to the unmet need, the added therapeutic value and the quality of evidence;
- variables that may have an influence on the final decision taken by the CTS, including:
  - the target disease: oncological (solid/hematological) disease or non-oncological disease (infectious/autoimmune/other diseases);
  - population: adult, pediatric, mixed;
  - rare disease (according to orphanet): yes or no;
  - number of “Summaries of Findings” (SoF) according to the GRADE system that reported the key information concerning the magnitudes of relative and absolute effects of the interventions examined, the amount of available evidence and the certainty (or quality) of available evidence;[12]
  - number of clinical studies considered;
  - number of randomized clinical trials (RCT), supporting the application for innovativeness;
  - number of observational studies, supporting the application for innovativeness;
- appraisal date.

1  
2  
3 We firstly calculated some descriptive statistics: frequencies and percentages for categorical  
4 variables; mean and median values, standard deviations (SD), quartiles and extreme values for  
5 continuous variables.  
6  
7

8  
9  
10 Afterwards, we scrutinized the role played by the above-mentioned variables on the  
11 innovativeness appraisal. Fully innovative and conditionally innovative appraisals were merged  
12 in a unique category denominated “innovative”, given the limited number of appraisal reports.  
13  
14 With reference to comparisons between groups (i.e., innovative vs. non-innovative outcome),  
15 categorical data were analyzed using a contingency table with the Chi-square or Fisher’s exact  
16 test, as appropriate. Continuous data were analyzed using a Student’s T-test, after checking for  
17 normal distribution (based on the Shapiro-Wilk statistic), or a Wilcoxon rank-sum test otherwise.  
18  
19 Finally, we developed a recursive algorithm for innovativeness, using a determinist approach to  
20 scrutinize the role played by the three above-mentioned criteria (unmet need, therapeutic added  
21 value, quality of the evidence). This approach was merely data-driven and the univariate  
22 analyses on the role played by the three domains on innovative status were the starting point to  
23 create the decision tree.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

#### 40 **Patient and Public Involvement**

41  
42 No patients were directly involved in this study.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

Detailed information for each of the 77 available appraisals are reported in Supplementary Table

1.

Figure 2 shows that appraisals were equally distributed among “fully innovative” (36% of the total), “conditionally innovative” (30%) and “not innovative” (34%). Cancer medicines were more often appraised as fully innovative (39%), whereas other drugs show a higher proportion of non-innovative status (29% cancer drugs were appraised not innovative, compared to 43% non-cancer treatments), but the difference was not significant ( $p=0.20$ ).

The role played on innovativeness status by the appraisal year, rare disease, target disease, target population, number of SoF, overall number of studies, number of RCT and Phase I/II studies is illustrated in Table 1.

**Table 1.** Variables detected on the appraisal document and innovativeness status (2017-2020).

	ALL DISEASES (n=77)				ONCOLOGY (n=49)				NON-ONCOLOGY (n=28)			
	<i>All medicines</i>	<i>Innovative<sup>a</sup></i>	<i>Not innovative</i>	<i>p-value<sup>b</sup></i>	<i>All medicines</i>	<i>Innovative<sup>a</sup></i>	<i>Not Innovative</i>	<i>p-value<sup>b</sup></i>	<i>All medicines</i>	<i>Innovative<sup>a</sup></i>	<i>Not Innovative</i>	<i>p-value<sup>b</sup></i>
<b>CTS appraisal year</b>	n (%)	n (%)	n (%)		n (%)	n (%)	n (%)		n (%)	n (%)	n (%)	
2017	28 (36.4)	18 (64.3)	10 (35.7)		18 (36.7)	12 (66.7)	6 (33.3)		10 (35.7)	6 (60.0)	4 (40.0)	
2018	25 (32.5)	17 (68.0)	8 (32.0)		15 (30.6)	10 (66.7)	5 (33.3)		10 (35.7)	7 (70.0)	3 (30.0)	
2019	24 (31.2)	16 (66.7)	8 (33.3)	0.96	16 (32.7)	13 (81.2)	3 (18.8)	0.57	8 (28.6)	3 (37.5)	5 (62.5)	0.37
<b>Rare disease</b>												
No	34 (44.2)	20 (58.8)	14 (41.2)		23 (46.9)	17 (73.9)	6 (26.1)		11 (39.3)	3 (27.3)	8 (72.7)	
Yes	43 (55.8)	31 (72.1)	12 (27.9)	0.22	26 (53.1)	18 (69.2)	8 (30.8)	0.72	17 (60.7)	13 (76.5)	4 (23.5)	0.02
<b>Disease</b>												
Solid tumours	30 (39.0)	21 (70.0)	9 (30.0)		30 (61.2)	21 (70.0)	9 (30.0)		-	-	-	
Hematological malignancies	19 (24.7)	14 (73.7)	5 (26.3)		19 (38.8)	14 (73.7)	5 (26.3)	0.78	-	-	-	
Infectious diseases	5 (6.5)	3 (60.0)	2 (40.0)		-	-	-		5 (17.9)	3 (60.0)	2 (40.0)	
Autoimmune diseases	3 (3.9)	1 (33.3)	2 (66.7)		-	-	-		3 (10.7)	1 (33.3)	2 (66.7)	

1													
2													
3	Other	20 (26.0)	12 (60.0)	8 (40.0)	0.64	-	-	-		20 (71.4)	12 (60.0)	8 (40.0)	0.68
4													
5	<b>Population</b>												
6													
7													
8	Adults only	65 (84.4)	42 (64.6)	23 (35.4)		46 (93.9)	33 (71.7)	13 (28.3)		19 (67.9)	9 (47.4)	10 (52.6)	
9													
10	Pediatric or mixed	12 (15.6)	9 (75.0)	3 (25.0)	0.74	3 (6.1)	2 (66.7)	1 (33.3)	0.99	9 (32.1)	7 (77.8)	2 (22.2)	0.22
11													
12	<b>Mean number SoF (SD)</b>	3.4 (2.9)	3.1 (2.6)	3.8 (3.4)	0.34	2.5 (2.2)	2.5 (2.2)	2.4 (2.1)	0.69	4.9 (3.4)	4.4 (2.8)	5.5 (4.0)	0.42
13													
14													
15	<b>N studies</b>												
16													
17	1	61 (79.2)	41 (67.2)	20 (32.8)		45 (91.8)	31 (68.9)	14 (31.1)		16 (57.1)	10 (62.5)	6 (37.5)	
18													
19	>1	16 (20.8)	10 (62.5)	6 (37.5)	0.72	4 (8.2)	4 (100.0)	0 (0.0)	0.31	12 (42.9)	6 (50.0)	6 (50.0)	0.51
20													
21													
22	<b>N RCT</b>												
23													
24	0	15 (19.5)	10 (66.7)	5 (33.3)		12 (24.5)	7 (58.3)	5 (41.7)		3 (10.7)	3 (100.0)	0 (0.0)	
25													
26	1	49 (63.6)	34 (69.4)	15 (30.6)		34 (69.4)	25 (73.5)	9 (26.5)		15 (53.6)	9 (60.0)	6 (40.0)	
27													
28	>1	13 (16.9)	7 (53.8)	6 (46.1)	0.57	3 (6.1)	3 (100.0)	0 (0.0)	0.32	10 (35.7)	4 (40.0)	6 (60.0)	0.17
29													
30													
31	<b>N clinical trials phase I/II</b>												
32													
33	0	59 (76.6)	38 (64.4)	21 (35.6)		37 (75.5)	28 (75.7)	9 (24.3)		22 (78.6)	10 (45.4)	12 (54.6)	
34													
35	≥1	18 (23.4)	13 (72.2)	5 (27.8)	0.54	12 (24.5)	7 (58.3)	5 (41.7)	0.29	6 (21.4)	6 (100.0)	0 (0.0)	0.02
36													
37													
38													
39													
40													
41													
42													
43													
44													
45													
46													
47													



1  
2  
3 <sup>a</sup> Innovative status includes fully and conditionally innovative.  
4  
5

6 <sup>b</sup> Comparisons between innovative and non-innovative outcome were performed using a contingency table with the Chi-square or Fisher's exact test,  
7  
8 as appropriate for categorical data. Continuous data were analyzed using a Student's T-test, after checking for normal distribution (based on the  
9  
10 Shapiro-Wilk statistic), or a Wilcoxon rank-sum test otherwise.  
11  
12  
13  
14  
15

16 CTS: Technical-scientific committee; SoF: Summaries of Findings; RCT: Randomized Clinical Trial  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

1  
2  
3 No significant association between innovativeness evaluation and the factors examined emerged  
4  
5 when all types of disease were considered together. A similar proportion of appraisals was  
6  
7 evaluated innovative with (66.1%) or without (66.7%) RCT evidence in support. Rare disease  
8  
9 and pediatric/mixed indications were appraised innovative by a larger proportion, although not  
10  
11 statistical significant. Furthermore, rarity of disease, and type of disease did not seem to be  
12  
13 determinant for the innovativeness evaluation. In the non-oncological setting, rare disease status  
14  
15 (p=0.02) and availability of one or more phase I/II studies (p=0.02) were more frequently  
16  
17 reported in the innovative indication group. Non-oncological forms have a higher number of  
18  
19 RCT supporting them compared to oncological ones (more than 1 RCT supporting 36% of non-  
20  
21 oncological ones compared to approximately 6% of oncological ones).  
22  
23  
24  
25

26 As a second step, we investigated the role of each of the three domains on appraisals. Table 2  
27  
28 shows the association between unmet therapeutic need, added therapeutic need and quality of  
29  
30 evidence and the final appraisal.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** Role played by the three domains on innovativeness status (2017-2020).

	<i>All medicines</i>	<i>Innovative</i>	<i>Not innovative</i>	<i>p-value<sup>b</sup></i>
<b>Unmet therapeutic need</b>				
N	77	51	26	
Maximum (Scale=1)	10 (13.0%)	7 (70.0%)	3 (30.0%)	
Important (Scale=2)	30 (39.0%)	22 (73.3%)	8 (26.7%)	
Moderate (Scale=3)	32 (41.6%)	22 (68.7%)	10 (31.2%)	
Poor (Scale=4)	5 (6.5%)	0 (0.0%)	5 (100.0%)	0.11
Range	1 - 4	1 - 3	1 - 4	
Mean (SD)	2.4 (0.8)	2.3 (0.7)	2.7 (0.9)	0.09
Median (Range IQ)	2 (2-3)	2 (2-3)	3 (2-3)	
<b>Added therapeutic value</b>				
N	76 <sup>c</sup>	51	25 <sup>c</sup>	
Maximum (Scale=1)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Important (Scale=2)	25 (32.9%)	24 (96.0%)	1 (4.0%)	
Moderate (Scale=3)	31 (40.8%)	27 (87.1%)	4 (12.9%)	
Poor (Scale=4)	19 (25.0%)	0 (0.0%)	19 (100.0%)	
Very Poor (Scale=5)	1 (1.3%)	0 (0.0%)	1 (100.0%)	<0.01

Range	2 - 5	2 - 3	2 - 5	
Mean (SD)	2.9 (0.8)	2.5 (0.5)	3.8 (0.6)	<0.01
Median (Range IQ)	3 (2-4)	3 (2-3)	4 (4-4)	

### Quality of clinical evidence

#### (GRADE evaluation)

N	77	51	26	
High (Scale=1)	11 (14.3%)	10 (90.9%)	1 (9.1%)	
Moderate (Scale=2)	42 (54.5%)	28 (66.7%)	14 (33.3%)	
Low (Scale=3)	18 (23.4%)	11 (61.1%)	7 (38.9%)	
Very low (Scale=4)	6 (7.8%)	2 (33.3%)	4 (66.7%)	0.11
Range	1 - 4	1 - 4	1 - 4	
Mean (SD)	2.2 (0.8)	2.1 (0.8)	2.5 (0.8)	0.03
Median (Range IQ)	2 (2-3)	2 (2-3)	2 (2-3)	

IQ: interquartile; SD: standard deviation

<sup>a</sup> Innovative status includes fully and conditionally innovative

<sup>b</sup> Comparisons between innovative and non-innovative outcome were performed using a contingency table with the Chi-square or Fisher's exact test, as appropriate for categorical data. Continuous data were analyzed using a Student's T-test, after checking for normal distribution (based on the Shapiro-Wilk statistic), or a Wilcoxon rank-sum test otherwise.

1  
2  
3     <sup>c</sup> For one rating (10-Nivolumab), the added therapeutic value was reported as “not assessable”.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 A significant difference between innovative and not innovative outcomes was found both for the  
4 added therapeutic value ( $p < 0.01$ ) and the quality of evidence domains ( $p = 0.03$ ). For  
5  
6 innovative and non-innovative indications, the added therapeutic value had an average score of  
7  
8 2.5 (between “Moderate” and “Important”) and 3.8 (between “Poor” and “Moderate”)  
9  
10 respectively. The quality of evidence for innovative and non-innovative medicines had an  
11  
12 average score of 2.1 (“Moderate”), and 2.5 (between “Low” and “Moderate”) respectively.  
13  
14 The average scores of unmet need for innovative and not innovative evaluations were not  
15  
16 significantly different ( $p = 0.09$ ), being respectively equal to 2.3 and 2.7 (both between  
17  
18 “Moderate” and “Important”).  
19  
20  
21  
22

23  
24 Taking into account the above-mentioned univariate findings, where added therapeutic value  
25  
26 ( $p < 0.01$ ) and quality of evidence ( $p = 0.03$ ) were associated to innovativeness status, a data-driven  
27  
28 decision tree using a deterministic approach was developed (Figure 3).  
29  
30

31  
32 The flowchart illustrated by Figure 3 confirms that added therapeutic value was the most  
33  
34 influential parameter, followed by GRADE evaluation, whereas the unmet therapeutic need had a  
35  
36 quite limited impact on the final appraisal. When the added therapeutic value was rated as "poor"  
37  
38 or "absent", or when the GRADE evaluation was "very low", the indication is never considered  
39  
40 innovative. Innovativeness resulted from an at least a "moderate" added therapeutic value  
41  
42 combined with an at least a "moderate" GRADE evaluation.  
43  
44

45  
46 The decision tree accounted for 63 out of 77 cases (82%). As for the other 14 appraisals, 8 of  
47  
48 them were either "conditionally innovative" or "not innovative" because they had "moderate"  
49  
50 added therapeutic value and a "low" GRADE evaluation. The other 6 cases were given either a  
51  
52 "full" or a "conditioned" innovativeness because they had a "moderate" added therapeutic value  
53  
54 along with a "high" GRADE evaluation. When the final assessment was uncertain, it was not  
55  
56  
57

1  
2  
3 possible to discern factors determining the final appraisal, nor to find out the driver from the  
4 characteristics of the indication, such as the disease (oncological or non-oncological) or the rarity  
5 of the disease. Finally, we found that for ultra-rare diseases ( $\leq 1$  patient per 100,000 people) very  
6 low quality of evidence was not an impediment to obtain innovativeness.  
7  
8  
9  
10  
11  
12  
13

## 14 **DISCUSSION**

15  
16  
17 The present study analyzed the new AIFA approach to appraise innovativeness for medicines.  
18 The appraisal process relies on three criteria: unmet therapeutic need, added therapeutic value,  
19 and quality of clinical evidence assessed with GRADE method. Despite the growing interest in  
20 this new appraisal process, there is still no evidence on the role played by the three criteria on the  
21 final decision, if these criteria have been consistently used overtime and if other variables do  
22 influence the innovativeness status. We found that added therapeutic value was the most  
23 influential parameter, followed by quality of evidence, whereas unmet therapeutic need had a  
24 quite limited impact on the final appraisal. It seems that a high unmet therapeutic need is  
25 perceived as a prerequisite of innovativeness, that drives the decision to apply for  
26 innovativeness, instead of being the driver of the appraisal process. Notwithstanding in five cases  
27 the unmet need had a poor rating, since its evaluation is not straightforward.[13] We investigated  
28 the potential role of other variables – namely the characteristics of the drugs and the evidence  
29 provided – that is whether there is a systematic correlation between these variables and  
30 innovativeness status. Some relationships were found: for examples, a larger proportion of drugs  
31 for rare diseases were appraised innovative. However, the statistical significance of these  
32 relationships is not reached. We have also investigated the general accuracy of the appraisal  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 process. Despite the high level of discretion left to the Scientific Committee in appraising the  
4  
5 unmet need and the added therapeutic value, this process looked generally coherent.  
6

7 Relying on a structured, transparent and replicable value framework to appraise new medicines is  
8  
9 a much debated topic. Value frameworks for health technologies have been investigated by the  
10  
11 literature[14] and huge efforts have been made to define clinical-value frameworks in specific  
12  
13 therapeutic areas, such as cancer drugs.[15] Despite there is a general consensus that unmet need  
14  
15 and clinical value are important value domains, it is still a matter of debate whether a threshold  
16  
17 for minimum clinical value (meaningful clinical benefit) should be set and used by regulatory  
18  
19 authorities,[16] as well as how other domains should be considered (e.g. patient reported  
20  
21 outcomes and acceptability to patients) and how different domains could be aggregated to  
22  
23 support operationally pricing based on value. [17,18]  
24  
25  
26  
27

28 Other European countries have relied on a formal appraisal of added therapeutic value. This is  
29  
30 done for example in France and Germany where all new drugs and indications are appraised and  
31  
32 added therapeutic value is ranked in five and six levels respectively.[1] Ranks are used for price /  
33  
34 discount negotiations. In France the absolute benefit is ranked too and used to take decisions on  
35  
36 reimbursement (introduction in the positive list and co-payment). There is evidence on the (i)  
37  
38 coherence between ranks attributed in the two countries to the same medicine,[19] consistency  
39  
40 between these rankings and other way of measuring added value by HTA organisations (e.g.  
41  
42 between the added therapeutic value rank in France and QALYs – Quality Adjusted Life Years  
43  
44 gained - in England[20]) and scientific societies[21] and the role played by the added therapeutic  
45  
46 value in price/discount negotiation.[22] Italy is the only country in Europe where (i)  
47  
48 innovativeness status is appraised on the grounds of a ranked unmet need, added therapeutic  
49  
50 value and quality of the evidence, (ii) innovative medicines are provided a speedier market access  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 and dedicated funds and (iii) added therapeutic value rank is not used in price negotiation. As a  
4  
5 consequence, our results, besides being the first one published on the Italian-case, cannot be fully  
6  
7 compared with that of our countries.  
8  
9

10 The study has some limitations. Firstly, it is based on a quite small number of appraisals. This  
11  
12 did not allow to analyze possible different patterns of association between the three  
13  
14 innovativeness criteria and the type of innovativeness (i.e., fully or conditionally innovative).  
15  
16 Only the availability of a larger number of innovativeness appraisals will allow to address this  
17  
18 issue.  
19  
20

21 As already mentioned, innovativeness appraisals can be requested by the companies or  
22  
23 spontaneously carried out by AIFA. The information on the applicant was not available and no  
24  
25 stratified analysis could be performed, despite it would have been very interesting. We could  
26  
27 analyze only the final appraisal published by AIFA, but we did not have any access to the  
28  
29 applications submitted by the companies. This implies that the results of the present study cannot  
30  
31 be considered a predictor of the response by AIFA to the applicant. However, our analysis was  
32  
33 aimed at evaluation of the key drivers and the consistency of the AIFA decision-making process,  
34  
35 rather than the comparison of applications submitted by the companies and final decision of  
36  
37 AIFA.  
38  
39  
40  
41

42 Despite the above-mentioned limitations, our analysis has some important implications.  
43  
44 Companies are pushed to provide solutions with an added therapeutic value and a high quality of  
45  
46 evidence, since the latter are the driver of innovativeness, which brings important advantages for  
47  
48 market access. We are aware that investments by the pharmaceutical companies are taken  
49  
50 globally, but the more HTA agencies insist on clear and transparent criteria to appraise new  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 medicines, the higher will be the impact on the management of pipelines by the pharmaceutical  
4  
5 companies.  
6

7  
8 The new process implemented by AIFA is also consistent with the need to rely on a pre-specified  
9  
10 value framework enhancing transparency, accountability and, because of its intrinsic  
11  
12 consistency, predictability of innovativeness appraisals.  
13  
14

15  
16 Last but not least, prioritization of access through innovativeness is managed transparently, on  
17  
18 the grounds of quite objective criteria and providing the whole stakeholders with the rationale of  
19  
20 decision taken.  
21  
22

## 23 24 25 26 27 28 29 **CONCLUSION**

30  
31  
32 To date, the new Italian innovativeness appraisal framework looked generally coherent and can  
33  
34 be considered an important step towards a more transparent and evidence-based management of  
35  
36 access to medicines in Italy. In the future, the process could be further enhanced, for example  
37  
38 including in a more structured framework patients reported outcome measures, which role is still  
39  
40 debated, whereas at present the appraisal process mostly relies on clinical variables, and proving  
41  
42 for an interaction between innovativeness (and its domains) appraisals and price negotiation.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Contributors:** CG, PB and CJ designed the study and developed the methods. CG and PB  
4 reviewed the literature. CG, PB and CJ contributed to the data analysis and interpretation. CG  
5 prepared the tables. CG and CJ drafted the manuscript. PB provided critical review of the  
6 manuscript. All authors have reviewed and approved the final version of the manuscript for  
7 publication.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

18 **Competing interests:** This research was partially funded by a grant from Celgene to Statinfo.  
19 CG is a senior consultant at Statinfo. CJ and PB have received a consultant fee from Celgene as  
20 scientific consultants for the project. Celgene was not involved in the preparation, drafting or  
21 editing of this manuscript.  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 **Data Statement:** Data are available in a public, open access repository. Appraisal reports on  
32 innovativeness are publicly downloadable from the AIFA's website at  
33 <https://www.aifa.gov.it/farmaci-innovativi>.  
34  
35  
36  
37  
38  
39  
40

41 **Funding:** This research was partially funded by a grant from Celgene to Statinfo. Award/Grant  
42 number is not applicable.  
43  
44  
45  
46  
47  
48  
49

50 **Acknowledgement:** The authors thank L. Benedan for her editorial assistance and M.  
51 Iannantuoni for providing graphic design assistance.  
52  
53  
54  
55  
56  
57

1  
2  
3 **Figure 1**  
4

5  
6 Criteria used to evaluate innovativeness adopted by Italian Medicines Agency.  
7  
8  
9

10  
11  
12  
13  
14  
15  
16  
17  
18 Adapted from Recchia, 2017  
19

20 \* For rare disease there is the following exception: the fully innovative is attributed in the  
21 presence of at least important unmet therapeutic need and added therapeutic value in presence of  
22 at least low quality of clinical evidence.  
23  
24  
25

26  
27 \*\* The innovativeness appraisal has to be decided on a case by case basis.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure 2**  
4  
5

6 Innovative appraisals by the Italian Medicines Agency (2017-2020).  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 3**

Deterministic decision tree based on the available innovativeness appraisals released by the Italian Medicines Agency (2017-2020).

For peer review only

## REFERENCES

- 1 Panteli D, Arickx F, Cleemput I, *et al.* Pharmaceutical regulation in 15 European countries review. *Heal Syst Transit* 2016;**18**:1–122.
- 2 Jommi C, Minghetti P. Pharmaceutical pricing policies in Italy. In: Babar Z-U-D, ed. *Pharmaceutical Prices in the 21st Century*. Adis, Cham: : Springer 2015. 131–50. doi:10.1007/978-3-319-12169-7\_8
- 3 AIFA. Criteri per la classificazione dei farmaci innovativi e dei farmaci oncologici innovativi ai sensi dell'articolo 1, comma 402, della legge 11 dicembre 2016, n. 232. 2017;:519.
- 4 Atkins D, Best D, Briss PA, *et al.* Grading quality of evidence and strength of recommendations. *BMJ* 2004;**328**:1490. doi:10.1136/bmj.328.7454.1490
- 5 Fortinguerra F, Tafuri G, Trotta F, *et al.* Using GRADE methodology to assess innovation of new medicinal products in Italy. *Br J Clin Pharmacol* 2019;**86**:93–105. doi:10.1111/bcp.14138
- 6 Di Marzio S. E l'AIFA tracciò la strada dell'innovatività. *AboutPharma* 2017;**148**:28–30.
- 7 Scavone C, Capuano A, Rossi F. New criteria of Italian Medicine Agency for the attribution of therapeutic innovation: viewpoint of the pharmacologist. *G Ital di Farm e Farm* 2017;**9**:5–12.
- 8 Urbinati D, Rova A, Cioni L. The impact of the new innovative algorithm in Italy. *Value Heal* 2018;**21**:S164. doi:10.1016/j.jval.2018.09.977
- 9 Sligh S. Italy's new pharmaceutical innovation ranking system: key criteria for

- 1  
2  
3 successfully achieving innovative status. *Value Heal* 2018;**21**:S196.  
4  
5 doi:10.1016/j.jval.2018.09.1168  
6  
7  
8  
9 10 Meremetidis A, Ferrario M, Giuliani G. The new AIFA innovation framework to  
10 recognize innovative drugs: a preliminary analysis of key drivers of evaluation. *Value*  
11  
12  
13 *Heal* 2018;**21**:S160. doi:10.1016/j.jval.2018.09.955  
14  
15  
16 11 Agenzia Italiana del Farmaco. Farmaci innovativi.  
17  
18  
19 12 The GRADE Working Group. *GRADE Handbook. Handbook for grading the quality of*  
20  
21  
22 *evidence and the strength of recommendations using the GRADE approach*. 2013.  
23  
24  
25 13 Vreman RA, Heikkinen I, Schuurman A, *et al*. Unmet Medical Need: an introduction to  
26  
27  
28 definitions and stakeholder perceptions. *Value Heal* 2019;**22**:1275–82.  
29  
30  
31 doi:10.1016/j.jval.2019.07.007  
32  
33  
34 14 Towse A, Barnsley P. Approaches to identifying, measuring, and aggregating elements of  
35  
36  
37 value. *Int J Technol Assess Health Care* 2013;**29**:360–4.  
38  
39  
40  
41 15 Cherny NI, de Vries EGE, Dafni U, *et al*. Comparative assessment of clinical benefit  
42  
43  
44 using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO Value  
45  
46  
47 Framework Net Health Benefit score. *J Clin Oncol* 2019;**37**:336–49.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 16 Grössmann N, Del Paggio JC, Wolf S, *et al*. Five years of EMA-approved systemic cancer  
therapies for solid tumours—a comparison of two thresholds for meaningful clinical  
benefit. *Eur J Cancer* 2017;**82**:66–71. doi:10.1016/j.ejca.2017.05.029



- 1  
2  
3 17 Jommi C, Armeni P, Costa F, *et al.* Implementation of value-based pricing for medicines.  
4  
5 *Clin Ther* 2020;**42**:15–24. doi:10.1016/j.clinthera.2019.11.006  
6  
7  
8  
9 18 Sussex J, Towse A, Devlin N. Operationalizing value-based pricing of medicines: a  
10 taxonomy of approaches. *Pharmacoeconomics* 2013;**31**:1–10. doi:10.1007/s40273-012-  
11 0001-x  
12  
13  
14  
15  
16 19 Ruof J, Schwartz FW, Schulenburg J-M, *et al.* Early benefit assessment (EBA) in  
17 Germany: analysing decisions 18 months after introducing the new AMNOG legislation.  
18  
19 *Eur J Heal Econ* 2014;**15**:577–89.  
20  
21  
22  
23 20 Drummond M, de Pouvourville G, Jones E, *et al.* A comparative analysis of two  
24 contrasting European approaches for rewarding the value added by drugs for cancer:  
25 England versus France. *Pharmacoeconomics* 2014;**32**:509–20.  
26  
27  
28  
29  
30  
31 21 Li J, Vivot A, Alter L, *et al.* Appraisal of cancer drugs: a comparison of the French health  
32 technology assessment with value frameworks of two oncology societies. *Expert Rev*  
33 *Pharmacoecon Outcomes Res* 2019;**26**:1–5.  
34  
35  
36  
37  
38  
39 22 Theidel U, von der Schulenburg JMG. Benefit assessment in Germany: implications for  
40 price discounts. *Health Econ Rev* 2016;**6**:1–12. doi:10.1186/s13561-016-0109-3  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Criteria used to evaluate innovativeness adopted by Italian Medicines Agency.

Adapted from Recchia, 2017

\* For rare disease there is the following exception: the fully innovative is attributed in the presence of at least important unmet therapeutic need and added therapeutic value in presence of at least low quality of clinical evidence.

\*\* The innovativeness appraisal has to be decided on a case by case basis.

494x333mm (300 x 300 DPI)




Figure 2. Innovative appraisals by the Italian Medicines Agency (2017-2020)

494x361mm (300 x 300 DPI)




Figure 3. Deterministic decision tree based on the available innovativeness appraisals released by the Italian Medicines Agency (2017-2020)

467x304mm (300 x 300 DPI)

Supplementary Table 1 – Description of medicine innovative appraisal, ordered by date of publication on AIFA's website – Last access 31 July 2020

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
1	daratumumab	H	Adult	Yes	July 2017	Not innovative	Important	Moderate	Low	<i>Although multiple myeloma is a rare disease (prevalence does not exceed 5 / 10,000) AIFA evaluated this medicine in a setting of non-rare disease</i>
2	glecaprevir and pibrentasvir	Non-Onco	Adult	No	July 2017	Fully innovative	Important	Important	Moderate	
3	obeticholic acid	Non-Onco	Adult	Yes	May 2017	Not innovative	Maximum	Poor	Low	
4	baricitinib	Non-Onco	Adult	No	June 2017	Not innovative	Moderate	Poor	High	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
5	nusinersen	Non-Onco	Pediatric	Yes	July 2017	Fully innovative	Maximum	Important	Low	
6	palbociclib	S	Adult	No	June 2017	Not innovative	Important	Poor	Moderate	
7	palbociclib	S	Adult	No	June 2017	Conditionally innovative	Moderate	Moderate	Moderate	
8	cenegermin	Non-Onco	Adult	Yes	November 2017	Fully innovative	Important	Important	Low	
9	ceftazidime / avibactam	Non-Onco	Adult	No	July 2017	Not innovative	Important	Poor	Low	
10	nivolumab	S	Adult	No	September 2017	Not innovative	Important	N/A	Low	<i>The added therapeutic value in this indication was considered not assessable</i>
11	allogeneic t cells genetically modified	H	Adult	Yes	September 2017	Not innovative	Moderate	Moderate	Very low	
12	daratumumab	H	Adult	Yes	October 2017	Fully innovative	Moderate	Important	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
13	sofosbuvir/ velpatasvir/ voxilaprevir	Non-Onco	Adult	No	July 2017	Fully innovative	Important	Important	Moderate	
14	adalimumab	Non-Onco	Adult	Yes	November 2017	Conditionally innovative	Important	Moderate	Moderate	
15	lenalidomide	H	Adult	Yes	September 2017	Conditionally innovative	Moderate	Moderate	Moderate	
16	inotuzumab ozagamicin	H	Adult	Yes	October 2017	Conditionally innovative	Moderate	Moderate	Moderate	
17	atezolizumab	S	Adult	No	November 2017	Fully innovative	Important	Moderate	High	
18	bezlotoxumab	Non-Onco	Adult	No	October 2017	Not innovative	Important	Moderate	Low	
19	dinutuximab beta	S	Mixed	Yes	February 2018	Fully innovative	Maximum	Important	Moderate	
20	dinutuximab beta	S	Mixed	Yes	February 2018	Not innovative	Maximum	Important	Very low	
21	alectinib	S	Adult	No	January 2018	Conditionally innovative	Moderate	Moderate	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
22	alectinib	S	Adult	No	January 2018	Fully innovative	Moderate	Important	Moderate	
23	nivolumab	S	Adult	No	November 2017	Conditionally innovative	Important	Moderate	Moderate	
24	midostaurin	H	Adult	Yes	December 2017	Fully innovative	Moderate	Important	Moderate	
25	midostaurin	H	Adult	Yes	December 2017	Not innovative	Important	Poor	Low	
26	ibrutinib	H	Adult	Yes	October 2017	Conditionally innovative	Moderate	Moderate	Moderate	
27	dupilumab	Non-Onco	Adult	No	January 2018	Fully innovative	Important	Moderate	High	
28	ocrelizumab	Non-Onco	Adult	No	February 2018	Not innovative	Maximum	Poor	Moderate	
29	letermovir	Non-Onco	Adult	Yes	February 2018	Fully innovative	Moderate	Important	High	
30	avelumab	S	Adult	Yes	January 2018	Conditionally innovative	Important	Moderate	Low	



ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
31	canakinumab	Non-Onco	Mixed	Yes	December 2017	Conditionally innovative	Important	Moderate	Moderate	
32	ibrutinib	H	Adult	Yes	July 2017	Not innovative	Poor	Poor	Moderate	
33	ribociclib	S	Adult	No	November 2017	Conditionally innovative	Moderate	Moderate	Moderate	
34	nivolumab	H	Adult	Yes	July 2017	Conditionally innovative	Maximum	Moderate	Low	
35	niraparib	S	Adult	Yes	January 2018	Conditionally innovative	Important	Moderate	Moderate	
36	regorafenib	S	Adult	No	February 2018	Conditionally innovative	Maximum	Moderate	High	
37	emicizumab	Non-Onco	Mixed	Yes	June 2018	Fully innovative	Moderate	Important	Low	
38	ethyl telotristat	S	Adult	Yes	January 2018	Not innovative	Important	Poor	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
39	liposomal daunorubicin hydrochloride / cytarabine	H	Adult	Yes	November 2018	Fully innovative	Moderate	Important	Moderate	
40	pembrolizumab	S	Adult	No	May 2019	Fully innovative	Moderate	Important	High	
41	tocilizumab	Non-Onco	Adult	Yes	July 2018	Conditionally innovative	Moderate	Moderate	Moderate	
42	daratumumab	H	Adult	Yes	October 2017	Fully innovative	Moderate	Important	Moderate	
43	cladribine	Non-Onco	Adult	No	April 2018	Not innovative	Moderate	Poor	Very low	
44	lutetium oxodotreotide	S	Adult	Yes	March 2018	Fully innovative	Important	Important	Low	
45	darvadstrocel	Non-Onco	Adult	Yes	April 2019	Not innovative	Moderate	Poor	Low	
46	cysteamine	Non-Onco	Mixed	Yes	January 2018	Not innovative	Poor	Moderate	Very low	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
47	obinutuzumab	H	Adult	Yes	March 2018	Not innovative	Poor	Poor	Moderate	
48	pembrolizumab	S	Adult	No	June 2018	Conditionally innovative	Important	Moderate	High	
49	pembrolizumab	H	Adult	Yes	November 2017	Conditionally innovative	Maximum	Moderate	Low	
50	pertuzumab	S	Adult	No	November 2018	Not innovative	Moderate	Poor	Moderate	
51	tisagenlecleucel	H	Mixed	Yes	January 2019	Fully innovative	Important	Important	Moderate	
52	tisagenlecleucel	H	Adult	Yes	January 2019	Fully innovative	Important	Important	Low	
53	burosumab	Non-Onco	Pediatric	Yes	December 2018	Conditionally innovative	Important	Moderate	Low	
54	durvalumab	S	Adult	No	March 2019	Fully innovative	Important	Important	Moderate	
55	lenvatinib	S	Adult	Yes	April 2019	Not innovative	Important	Absent	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
56	brentuximab vedotin	H	Adult	Yes	April 2018	Conditionally innovative	Moderate	Moderate	Moderate	
57	pembrolizumab	S	Adult	No	May 2019	Fully innovative	Important	Moderate	High	
58	pembrolizumab	S	Adult	No	May 2019	Fully innovative	Moderate	Important	Moderate	
59	nivolumab	S	Adult	No	April 2019	Fully innovative	Important	Moderate	High	
60	osimertinib	S	Adult	No	February 2019	Fully innovative	Moderate	Important	Moderate	
61	axicabtagene ciloleucel	H	Adult	Yes	January 2019	Fully innovative	Important	Important	Moderate	
62	dabrafenib	S	Adult	No	April 2019	Fully innovative	Important	Important	High	
63	trametinib	S	Adult	No	April 2019	Fully innovative	Important	Important	High	
64	doravirina/ lamivudina/ tenofovir disoproxil	Non-Onco	Adult	No	May 2019	Not innovative	Poor	Poor	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
65	doravirine	Non-Onco	Adult	No	May 2019	Not innovative	Poor	Poor	Moderate	
66	venetoclax	H	Adult	Yes	April 2019	Conditionally innovative	Moderate	Moderate	Moderate	
67	abemaciclib	S	Adult	No	May 2019	Conditionally innovative	Moderate	Moderate	Moderate	
68	caplacizumab	Non-Onco	Adult	Yes	February 2019	Conditionally innovative	Moderate	Moderate	Low	
69	patisiran	Non-Onco	Adult	Yes	November 2018	Fully innovative	Important	Important	Moderate	
70	emicizumab	Non-Onco	Mixed	Yes	October 2019	Conditionally innovative	Moderate	Moderate	Low	
71	metreleptin	Non-Onco	Mixed	Yes	February 2019	Conditionally innovative	Maximum	Moderate	Very low	<i>Ultra-rare disease</i>
72	abiraterone acetate	S	Adult	No	May 2018	Not innovative	Moderate	Poor	Moderate	
73	alirocumab	Non-Onco	Adult	No	November 2019	Not innovative	Moderate	Poor	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
74	encorafenib	S	Adult	No	May 2019	Not innovative	Moderate	Poor	Moderate	
75	binimetinib	S	Adult	No	May 2019	Not innovative	Moderate	Poor	Moderate	
76	lanadelumab	Non-Onco	Mixed	Yes	December 2019	Not innovative	Moderate	Poor	Moderate	
77	cerliponase alfa	Non-Onco	Pediatric	Yes	December 2018	Fully innovative	Maximum	Important	Very low	<i>Ultra-rare disease</i>

\* according to orphanet

AIFA: italian medicines agency; CTS: technical-scientific committee; H: hematological malignancies; S: solid tumor; onco: oncological disease; non-onco: non oncological disease

# BMJ Open

## KEY DRIVERS OF INNOVATIVENESS APPRAISAL FOR MEDICINES: THE ITALIAN EXPERIENCE AFTER THE ADOPTION OF THE NEW RANKING SYSTEM

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041259.R2
Article Type:	Original research
Date Submitted by the Author:	01-Dec-2020
Complete List of Authors:	Galeone, Carlotta; Università degli Studi di Milano-Bicocca, Bicocca Applied Statistics Center (B-ASC) Bruzzi, Paolo; IRCCS AOU San Martino, Department of Clinical Epidemiology Jommi, Claudio; Università Bocconi CERGAS, SDA Bocconi School of Management
<b>Primary Subject Heading</b>:	Health policy
Secondary Subject Heading:	Public health
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3 **KEY DRIVERS OF INNOVATIVENESS APPRAISAL FOR MEDICINES: THE**  
4  
5 **ITALIAN EXPERIENCE AFTER THE ADOPTION OF THE NEW RANKING SYSTEM**  
6  
7  
8  
9  
10

11 **Running title:** Innovativeness appraisal for medicines in Italy  
12  
13

14  
15  
16  
17 Carlotta Galeone, Paolo Bruzzi, Claudio Jommi  
18  
19  
20  
21  
22  
23  
24

25 **Carlotta Galeone**

26  
27 Biostatistics & Outcome Research Unit  
28

29 Statinfo  
30

31 Renate (MB)  
32  
33

34 Italy  
35  
36  
37  
38  
39  
40

41 **Paolo Bruzzi**

42  
43 Department of Clinical Epidemiology  
44

45 IRCCS San Martino - IST,  
46

47 Genoa  
48  
49

50 Italy  
51  
52  
53  
54

55 **Claudio Jommi**  
56  
57

1  
2  
3 Cergas (Centre for Research on Health and Social Care Management), SDA Bocconi School of  
4  
5 Management,  
6  
7 Bocconi University,  
8  
9 Milan  
10  
11  
12 Italy.  
13  
14  
15  
16  
17  
18

19 **Corresponding Author:**

20  
21 Carlotta Galeone, *PhD ScD*

22  
23 Biostatistics & Outcome Research Unit, Statinfo

24  
25 Via Concordia 6, 20838 Renate (MB)

26  
27  
28 Phone: +39 (0)3629238209

29  
30  
31 Fax: +39 (0)3629238205

32  
33 carlotta.galeone@statinfo.org  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** In 2017, the Italian Medicines Agency (AIFA) introduced a standardized process to appraise innovativeness of medicines. Innovative medicines are provided speedier market access and dedicated funds. Innovativeness criteria are: unmet therapeutic need, added therapeutic value and quality of the evidence (GRADE method). We investigated the role played by these three criteria on the final decision aimed to understand how the new Italian innovativeness appraisal framework was implemented.

**Design:** A desk research gathered AIFA's appraisals reports on innovativeness and data analyses were conducted. No patients were directly involved in this study.

**Setting and Participants:** We scrutinized all 77 appraisals reports available on AIFA's website (2017-2020).

**Primary and secondary outcome measures:** The impact of the three domains on final decision was investigated through a series of univariate analyses.

**Results:** Among 77 appraisal reports on innovativeness available, 49 (64%) and 28 (36%) were for oncology and non-oncology medicines, respectively. The appraisals were equally distributed among "fully innovative" (36%), "conditionally innovative" (30%) and "not innovative" (34%). Added therapeutic value was the most important driver on innovativeness decision, followed by quality of the evidence. Drugs for rare diseases and with pediatric/mixed indications were appraised 'innovative' by a larger proportion, but no statistical significance was found.

**Conclusions:** Despite some limitations, including the moderate number of appraisals, this paper provides an insight into the determinants of innovativeness appraisals for medicines in Italy and the accuracy of the appraisal process. This has important implications in terms of transparency and accountability in the prioritization process applied to innovative medicines.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- This is an original, up to date analysis of the new National Drugs Agency appraisals framework for drug innovativeness in the Italian setting
- This study was based on a limited number of appraisals, but we systematically considered all the available ones
- The relatively small number of appraisals did not allow to analyze possible different patterns of association between the three innovativeness criteria and the type of innovativeness (i.e., fully or conditionally innovative)

## INTRODUCTION

Market Access for pharmaceuticals in Italy is managed by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA). AIFA, differently from most other European Countries medicines agencies, have both regulatory and access competences.[1] The latter include the negotiation of reimbursement, ex-factory price and managed entry agreements and the appraisal of innovativeness status, possibly required by the pharmaceutical companies at market launch or autonomously carried out by AIFA.[2] Innovativeness status has some advantages from an access perspective, including two dedicated funds (one for cancer medicines and the other for non-cancer medicines) and immediate access to regional markets.

The criteria to get innovativeness status, which can be attributed only to drugs indicated for serious illnesses (*life-threatening diseases; diseases producing frequent hospitalizations or causing disabilities that can seriously compromise quality of life*) are the unmet therapeutic need, the added therapeutic value and the quality of the evidence (Determina AIFA 519/2017).[3]

The **unmet therapeutic need** is rated as:

- *Maximum*: there are no alternatives for that specific indication;
- *Important*: there are a few alternatives, but with no impact on clinically relevant endpoints;
- *Moderate*: there are alternatives with a limited and/or uncertain or unreliable impact on clinically relevant endpoints;
- *Poor*: there are alternatives for the same indication with clinically proven reliable results;
- *Absent*: there are alternatives for the same indication with an important impact on the natural history of the disease.

The added **therapeutic value**, that refers to clinical benefit, can be rated as:

- *Maximum*: the new drug has proven larger efficacy than any possible existing alternatives. In this case, the treatment is able to either cure the illness or significantly alter its natural history;
- *Important*: the new drug has a proven larger efficacy measured on clinically relevant endpoints, decreases the risk of invalidating or fatal complications, avoids highly dangerous clinical procedures or has more favorable risk/benefit (R/B) ratio than any available alternatives. In a subset of patients, the treatment either modifies the natural history of the disease or is beneficial in other clinically significant ways, e.g. in terms of quality of life or disease-free intervals, when compared to available alternatives;
- *Moderate*: the new drug has a larger efficacy than any available alternatives, but it is only moderate or only proven in some subsets of patients, with limited impact on the quality of life;
- *Poor*: the new drug has either a limited improvement of efficacy or has been proven on endpoints which are not clinically relevant. Minor advantages, e.g. more acceptable administration route;
- *Absent*: the new drug has no relevant benefit when compared to other available treatments.

Endpoints relevance has been specified for cancer medicines, being overall survival (OS) considered the gold standard, and the lack of OS data needed to justify. The document quotes that progression-free survival (PFS), disease-free survival (DFS), full response time or other surrogated endpoints (with already established clinical benefits) may be taken into account,

1  
2  
3 according to indication and settings. Toxicity is also considered to evaluate the treatment's  
4  
5 adequacy.  
6

7  
8 To appraise the **quality of evidence**, AIFA has chosen the Grading of Recommendations  
9  
10 Assessment, Development and Evaluation (GRADE) method.[4] According to this approach, the  
11  
12 quality of clinical evidence can be graded as high, moderate, low or very low. The choice of  
13  
14 GRADE methodology was aimed at improving the transparency and reproducibility of the  
15  
16 appraisal process; this structured and flexible methodological tool provides a systematic  
17  
18 approach in the assessment and is meant to minimize biases and improve consistency of the  
19  
20 decisions.[5]  
21  
22

23  
24 The innovativeness is appraised per indication, and the innovativeness status lasts three years.  
25  
26 The appraisal model represents a common framework for all indications, even if safeguard  
27  
28 clauses are provided for rare indications where the quality of the evidence is more likely to be  
29  
30 lower.  
31  
32

33  
34 The industry usually applies for innovativeness, even if AIFA can proceed to evaluate it  
35  
36 regardless of the industry' application. The innovativeness request is appraised by the AIFA's  
37  
38 Technical-Scientific Committee (CTS). CTS may decide for full innovativeness, conditional  
39  
40 innovativeness or non-innovative. Conditionally innovative medicines share with fully  
41  
42 innovative medicines only the immediate access to regional markets. Conditional innovativeness  
43  
44 is granted when the evidence is not sufficiently mature to provide a full innovativeness status and  
45  
46 lasts 18 months.  
47  
48

49  
50 Despite the growing interest in this new criteria and the relevant appraisal process,[6] to our  
51  
52 knowledge only preliminary descriptive analyses (based on less of 20 innovativeness appraisals  
53  
54 updated to 2018) were available[7–9] and no clear and robust evidence emerged on the role  
55  
56  
57

1  
2  
3 played by the three criteria on the final decision, if these criteria have been consistently used  
4  
5 over time and if other variables influence the innovativeness status.  
6

7  
8 Our analyses, based on available innovativeness appraisals updated to July 2020, aim to cover  
9  
10 these information gaps and, more in general, to understand how the new Italian innovativeness  
11  
12 appraisal framework was implemented.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## METHODS

The new decision rule adopted by AIFA (Figure 1)[10] consists to grant innovativeness if both unmet need and added therapeutic value are graded “Maximum” or “Important” and the quality of evidence is rated “High” (green zone). Conversely, if the unmet need or the added therapeutic value are graded “Poor” or “Absent”, or the quality of evidence is rated “Low” or “Very Low” innovativeness will be not granted (red zone). For rare indications, the innovative status may be granted even if the quality of evidence is graded “Low”, but the unmet need and the added therapeutic value are both at least “Important”. To note, in the intermediate situations (grey zone) there is uncertainty about innovation status, and AIFA decides case-by-case.

Pharmaceutical companies are informed by AIFA on the intended final appraisal and can rebut on appraisals in ten days. The final appraisal is published on the AIFA’s website, together with a short description of the rationale behind the decision taken ([www.aifa.gov.it](http://www.aifa.gov.it)). These appraisals are written in Italian only. An English version should be desirable to allow greater dissemination of information outside Italy.

Appraisal reports on innovativeness were downloaded from the AIFA’s website[11] as at 31 July 2020: 77 appraisal reports were found, 49 and 28 for oncology and non-oncology medicines, respectively.

The following data were retrieved from the appraisal reports and inserted into an extraction template:

- final appraisal (“fully innovative”, “conditionally innovative” or “not innovative”);
- rank attributed to the unmet need, the added therapeutic value and the quality of evidence;
- variables that may have an influence on the final decision taken by the CTS, including:

- the target disease: oncological (solid/hematological) disease or non-oncological disease (infectious/autoimmune/other diseases);
- population: adult, pediatric, mixed;
- rare disease (according to orphanet): yes or no;
- number of “Summaries of Findings” (SoF) according to the GRADE system that reported the key information concerning the magnitudes of relative and absolute effects of the interventions examined, the amount of available evidence and the certainty (or quality) of available evidence;[12]
- number of clinical studies considered;
- number of randomized clinical trials (RCT), supporting the application for innovativeness;
- number of observational studies, supporting the application for innovativeness;
- appraisal date.

We firstly calculated some descriptive statistics: frequencies and percentages for categorical variables; mean and median values, standard deviations (SD), quartiles and extreme values for continuous variables.

Afterwards, we scrutinized the role played by the above-mentioned variables on the innovativeness appraisal. Fully innovative and conditionally innovative appraisals were merged in a unique category denominated “innovative”, given the limited number of appraisal reports. With reference to comparisons between groups (i.e., innovative vs. non-innovative outcome), categorical data were analyzed using a contingency table with the Chi-square or Fisher’s exact test, as appropriate. Continuous data were analyzed using a Student’s T-test, after checking for normal distribution (based on the Shapiro-Wilk statistic), or a Wilcoxon rank-sum test otherwise.

1  
2  
3 With reference to the primary aim of this study, i.e., the role played by the three domains on  
4 innovativeness status (innovativeness vs not innovativeness), we decided *a-priori* to compare  
5 groups by using the test for continuous variables, that has a higher power to detect possible  
6 differences in this set of preliminary analyses. In fact, the Fisher's exact test has low power to  
7 detect associations, i.e., the probability of obtaining false negative conclusions (type II error) is  
8 high.  
9

10  
11 Finally, we developed a recursive algorithm for innovativeness, using a determinist approach to  
12 scrutinize the role played by the three above-mentioned criteria (unmet need, therapeutic added  
13 value, quality of the evidence). This approach was merely data-driven and the univariate  
14 analyses on the role played by the three domains on innovative status were the starting point to  
15 create the decision tree.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Patient and Public Involvement**

31 No patients were directly involved in this study.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

Detailed information for each of the 77 available appraisals are reported in Supplementary Table

1.

Figure 2 shows that appraisals were equally distributed among “fully innovative” (36% of the total), “conditionally innovative” (30%) and “not innovative” (34%). Cancer medicines were more often appraised as fully innovative (39%), whereas other drugs show a higher proportion of non-innovative status (29% cancer drugs were appraised not innovative, compared to 43% non-cancer treatments), but the difference was not significant ( $p=0.20$ ).

The role played on innovativeness status by the appraisal year, rare disease, target disease, target population, number of SoF, overall number of studies, number of RCT and Phase I/II studies is illustrated in Table 1.

**Table 1.** Variables detected on the appraisal document and innovativeness status (2017-2020).

	ALL DISEASES (n=77)				ONCOLOGY (n=49)				NON-ONCOLOGY (n=28)			
	<i>All medicines</i>	<i>Innovative<sup>a</sup></i>	<i>Not innovative</i>	<i>p-value<sup>b</sup></i>	<i>All medicines</i>	<i>Innovative<sup>a</sup></i>	<i>Not Innovative</i>	<i>p-value<sup>b</sup></i>	<i>All medicines</i>	<i>Innovative<sup>a</sup></i>	<i>Not Innovative</i>	<i>p-value<sup>b</sup></i>
<b>CTS appraisal year</b>	n (%)	n (%)	n (%)		n (%)	n (%)	n (%)		n (%)	n (%)	n (%)	
2017	28 (36.4)	18 (64.3)	10 (35.7)		18 (36.7)	12 (66.7)	6 (33.3)		10 (35.7)	6 (60.0)	4 (40.0)	
2018	25 (32.5)	17 (68.0)	8 (32.0)		15 (30.6)	10 (66.7)	5 (33.3)		10 (35.7)	7 (70.0)	3 (30.0)	
2019	24 (31.2)	16 (66.7)	8 (33.3)	0.96	16 (32.7)	13 (81.2)	3 (18.8)	0.57	8 (28.6)	3 (37.5)	5 (62.5)	0.37
<b>Rare disease</b>												
No	34 (44.2)	20 (58.8)	14 (41.2)		23 (46.9)	17 (73.9)	6 (26.1)		11 (39.3)	3 (27.3)	8 (72.7)	
Yes	43 (55.8)	31 (72.1)	12 (27.9)	0.22	26 (53.1)	18 (69.2)	8 (30.8)	0.72	17 (60.7)	13 (76.5)	4 (23.5)	0.02
<b>Disease</b>												
Solid tumours	30 (39.0)	21 (70.0)	9 (30.0)		30 (61.2)	21 (70.0)	9 (30.0)		-	-	-	
Hematological malignancies	19 (24.7)	14 (73.7)	5 (26.3)		19 (38.8)	14 (73.7)	5 (26.3)	0.78	-	-	-	
Infectious diseases	5 (6.5)	3 (60.0)	2 (40.0)		-	-	-		5 (17.9)	3 (60.0)	2 (40.0)	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Autoimmune diseases	3 (3.9)	1 (33.3)	2 (66.7)		-	-	-		3 (10.7)	1 (33.3)	2 (66.7)	
Other	20 (26.0)	12 (60.0)	8 (40.0)	0.64	-	-	-		20 (71.4)	12 (60.0)	8 (40.0)	0.68
<b>Population</b>												
Adults only	65 (84.4)	42 (64.6)	23 (35.4)		46 (93.9)	33 (71.7)	13 (28.3)		19 (67.9)	9 (47.4)	10 (52.6)	
Pediatric or mixed	12 (15.6)	9 (75.0)	3 (25.0)	0.74	3 (6.1)	2 (66.7)	1 (33.3)	0.99	9 (32.1)	7 (77.8)	2 (22.2)	0.22
<b>Mean number SoF (SD)</b>	3.4 (2.9)	3.1 (2.6)	3.8 (3.4)	0.34	2.5 (2.2)	2.5 (2.2)	2.4 (2.1)	0.69	4.9 (3.4)	4.4 (2.8)	5.5 (4.0)	0.42
<b>N studies</b>												
1	61 (79.2)	41 (67.2)	20 (32.8)		45 (91.8)	31 (68.9)	14 (31.1)		16 (57.1)	10 (62.5)	6 (37.5)	
>1	16 (20.8)	10 (62.5)	6 (37.5)	0.72	4 (8.2)	4 (100.0)	0 (0.0)	0.31	12 (42.9)	6 (50.0)	6 (50.0)	0.51
<b>N RCT</b>												
0	15 (19.5)	10 (66.7)	5 (33.3)		12 (24.5)	7 (58.3)	5 (41.7)		3 (10.7)	3 (100.0)	0 (0.0)	
1	49 (63.6)	34 (69.4)	15 (30.6)		34 (69.4)	25 (73.5)	9 (26.5)		15 (53.6)	9 (60.0)	6 (40.0)	
>1	13 (16.9)	7 (53.8)	6 (46.1)	0.57	3 (6.1)	3 (100.0)	0 (0.0)	0.32	10 (35.7)	4 (40.0)	6 (60.0)	0.17
<b>N clinical trials phase I/II</b>												
0	59 (76.6)	38 (64.4)	21 (35.6)		37 (75.5)	28 (75.7)	9 (24.3)		22 (78.6)	10 (45.4)	12 (54.6)	

1													
2													
3	≥1	18 (23.4)	13 (72.2)	5 (27.8)	0.54	12 (24.5)	7 (58.3)	5 (41.7)	0.29	6 (21.4)	6 (100.0)	0 (0.0)	0.02
4													
5	<hr/>												
6													
7													
8													
9	<sup>a</sup> Innovative status includes fully and conditionally innovative.												
10													
11	<sup>b</sup> Comparisons between innovative and non-innovative outcome were performed using a contingency table with the Chi-square or Fisher's exact test,												
12	as appropriate for categorical data. Continuous data were analyzed using a Student's T-test, after checking for normal distribution (based on the												
13	Shapiro-Wilk statistic), or a Wilcoxon rank-sum test otherwise.												
14													
15													
16													
17													
18													
19													
20													
21	CTS: Technical-scientific committee; SoF: Summaries of Findings; RCT: Randomized Clinical Trial												
22													
23													
24													
25													
26													
27													
28													
29													
30													
31													
32													
33													
34													
35													
36													
37													
38													
39													
40													
41													
42													
43													
44													
45													
46													

1  
2  
3 No significant association between innovativeness evaluation and the factors examined emerged  
4  
5 when all types of disease were considered together. A similar proportion of appraisals was evaluated  
6  
7 innovative with (66.1%) or without (66.7%) RCT evidence in support. Rare disease and  
8  
9 pediatric/mixed indications were appraised innovative by a larger proportion, although not statistical  
10  
11 significant. Furthermore, rarity of disease, and type of disease did not seem to be determinant for the  
12  
13 innovativeness evaluation. In the non-oncological setting, rare disease status ( $p=0.02$ ) and  
14  
15 availability of one or more phase I/II studies ( $p=0.02$ ) were more frequently reported in the  
16  
17 innovative indication group. Non-oncological forms have a higher number of RCT supporting them  
18  
19 compared to oncological ones (more than 1 RCT supporting 36% of non-oncological ones compared  
20  
21 to approximately 6% of oncological ones).  
22  
23  
24

25  
26 As a second step, we investigated the role of each of the three domains on appraisals. Table 2 shows  
27  
28 the association between unmet therapeutic need, added therapeutic need and quality of evidence and  
29  
30 the final appraisal.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 2.** Role played by the three domains on innovativeness status (2017-2020).

	<i>All medicines</i>	<i>Innovative</i>	<i>Not innovative</i>	<i>p-value<sup>b</sup></i>
<b>Unmet therapeutic need</b>				
N	77	51	26	
Maximum (Scale=1)	10 (13.0%)	7 (70.0%)	3 (30.0%)	
Important (Scale=2)	30 (39.0%)	22 (73.3%)	8 (26.7%)	
Moderate (Scale=3)	32 (41.6%)	22 (68.7%)	10 (31.2%)	
Poor (Scale=4)	5 (6.5%)	0 (0.0%)	5 (100.0%)	
Range	1 - 4	1 - 3	1 - 4	
Mean (SD)	2.4 (0.8)	2.3 (0.7)	2.7 (0.9)	0.09
Median (Range IQ)	2 (2-3)	2 (2-3)	3 (2-3)	
<b>Added therapeutic value</b>				
N	76 <sup>c</sup>	51	25 <sup>c</sup>	
Maximum (Scale=1)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Important (Scale=2)	25 (32.9%)	24 (96.0%)	1 (4.0%)	
Moderate (Scale=3)	31 (40.8%)	27 (87.1%)	4 (12.9%)	
Poor (Scale=4)	19 (25.0%)	0 (0.0%)	19 (100.0%)	
Very Poor (Scale=5)	1 (1.3%)	0 (0.0%)	1 (100.0%)	
Range	2 - 5	2 - 3	2 - 5	

1  
2  
3  
4  
5  
6 Mean (SD) 2.9 (0.8) 2.5 (0.5) 3.8 (0.6) <0.01

7  
8  
9 Median (Range IQ) 3 (2-4) 3 (2-3) 4 (4-4)

10  
11 **Quality of clinical evidence**

12  
13  
14 **(GRADE evaluation)**

15  
16  
17 N 77 51 26

18  
19  
20 High (Scale=1) 11 (14.3%) 10 (90.9%) 1 (9.1%)

21  
22  
23 Moderate (Scale=2) 42 (54.5%) 28 (66.7%) 14 (33.3%)

24  
25  
26 Low (Scale=3) 18 (23.4%) 11 (61.1%) 7 (38.9%)

27  
28  
29 Very low (Scale=4) 6 (7.8%) 2 (33.3%) 4 (66.7%)

30  
31  
32 Range 1 - 4 1 - 4 1 - 4

33  
34  
35  
36 Mean (SD) 2.2 (0.8) 2.1 (0.8) 2.5 (0.8) 0.03

37  
38  
39 Median (Range IQ) 2 (2-3) 2 (2-3) 2 (2-3)

---

40  
41  
42  
43  
44  
45 IQ: interquartile; SD: standard deviation

46  
47  
48 <sup>a</sup> Innovative status includes fully and conditionally innovative

49  
50  
51 <sup>b</sup> Comparisons between innovative and non-innovative outcome were performed using a Student's T-  
52  
53 test, after checking for normal distribution (based on the Shapiro-Wilk statistic), or a Wilcoxon rank-  
54  
55 sum test otherwise.

56  
57  
58 <sup>c</sup> For one rating (10-Nivolumab), the added therapeutic value was reported as "not assessable".

1  
2  
3 A significant difference between innovative and not innovative outcomes was found both for the  
4 added therapeutic value ( $p < 0.01$ ) and the quality of evidence domains ( $p = 0.03$ ). For innovative  
5 and non-innovative indications, the added therapeutic value had an average score of 2.5 (between  
6 “Moderate” and “Important”) and 3.8 (between “Poor” and “Moderate”) respectively. The quality of  
7 evidence for innovative and non-innovative medicines had an average score of 2.1 (“Moderate”), and  
8 2.5 (between “Low” and “Moderate”) respectively. The average scores of unmet need for innovative  
9 and not innovative evaluations were not significantly different ( $p = 0.09$ ), being respectively equal to  
10 2.3 and 2.7 (both between “Moderate” and “Important”).

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21 Taking into account the above-mentioned univariate findings, where added therapeutic value  
22 ( $p < 0.01$ ) and quality of evidence ( $p = 0.03$ ) were associated to innovativeness status, a data-driven  
23 decision tree using a deterministic approach was developed (Supplementary Figure 1). The decision  
24 tree did not explicate all the appraisals final decision but accounted for 63 out of 77 cases (82%). As  
25 for the other 14 appraisals, 8 of them were either "conditionally innovative" or "not innovative"  
26 because they had "moderate" added therapeutic value and a "low" GRADE evaluation. The other 6  
27 cases were given either a "full" or a "conditioned" innovativeness because they had a "moderate"  
28 added therapeutic value along with a "high" GRADE evaluation. When the final assessment was  
29 uncertain, it was not possible to discern factors determining the final appraisal, nor to find out the  
30 driver from the characteristics of the indication, such as the disease (oncological or non-oncological)  
31 or the rarity of the disease. Finally, we found that for ultra-rare diseases ( $\leq 1$  patient per 100,000  
32 people) very low quality of evidence was not an impediment to obtain innovativeness.

## 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 **DISCUSSION**

52  
53  
54 The present study analyzed the new AIFA approach to appraise innovativeness for medicines. The  
55 appraisal process relies on three criteria: unmet therapeutic need, added therapeutic value, and  
56 quality of clinical evidence assessed with GRADE method. Despite the growing interest in this new  
57  
58  
59  
60

1  
2  
3 appraisal process, there is still no evidence on the role played by the three criteria on the final  
4  
5 decision, if these criteria have been consistently used overtime and if other variables do influence the  
6  
7 innovativeness status. We found that added therapeutic value was the most influential parameter,  
8  
9 followed by quality of evidence, whereas unmet therapeutic need had a quite limited impact on the  
10  
11 final appraisal. It seems that a high unmet therapeutic need is perceived as a prerequisite of  
12  
13 innovativeness, that drives the decision to apply for innovativeness, instead of being the driver of the  
14  
15 appraisal process. Notwithstanding in five cases the unmet need had a poor rating, since its  
16  
17 evaluation is not straightforward.[13] We investigated the potential role of other variables – namely  
18  
19 the characteristics of the drugs and the evidence provided – that is whether there is a systematic  
20  
21 correlation between these variables and innovativeness status. Some relationships were found: for  
22  
23 examples, a larger proportion of drugs for rare diseases were appraised innovative. However, the  
24  
25 statistical significance of these relationships is not reached. We have also investigated the general  
26  
27 accuracy of the appraisal process. Despite the high level of discretion left to the Scientific Committee  
28  
29 in appraising the unmet need and the added therapeutic value, this process looked generally coherent.  
30  
31 Relying on a structured, transparent and replicable value framework to appraise new medicines is a  
32  
33 much debated topic. Value frameworks for health technologies have been investigated by the  
34  
35 literature[14] and huge efforts have been made to define clinical-value frameworks in specific  
36  
37 therapeutic areas, such as cancer drugs.[15] Despite there is a general consensus that unmet need and  
38  
39 clinical value are important value domains, it is still a matter of debate whether a threshold for  
40  
41 minimum clinical value (meaningful clinical benefit) should be set and used by regulatory  
42  
43 authorities,[16] as well as how other domains should be considered (e.g. patient reported outcomes  
44  
45 and acceptability to patients) and how different domains could be aggregated to support  
46  
47 operationally pricing based on value. [17,18]  
48  
49 Other European countries have relied on a formal appraisal of added therapeutic value. This is done  
50  
51 for example in France and Germany where all new drugs and indications are appraised and added  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 therapeutic value is ranked in five and six levels respectively.[1] Ranks are used for price / discount  
4 negotiations. In France the absolute benefit is ranked too and used to take decisions on  
5 reimbursement (introduction in the positive list and co-payment). There is evidence on the (i)  
6 coherence between ranks attributed in the two countries to the same medicine,[19] consistency  
7 between these rankings and other way of measuring added value by HTA organisations (e.g. between  
8 the added therapeutic value rank in France and QALYs – Quality Adjusted Life Years gained - in  
9 England[20]) and scientific societies[21] and the role played by the added therapeutic value in  
10 price/discount negotiation.[22] Italy is the only country in Europe where (i) innovativeness status is  
11 appraised on the grounds of a ranked unmet need, added therapeutic value and quality of the  
12 evidence, (ii) innovative medicines are provided a speeder market access and dedicated funds and  
13 (iii) added therapeutic value rank is not used in price negotiation. As a consequence, our results,  
14 besides being the first one published on the Italian-case, cannot be fully compared with that of our  
15 countries.

16  
17 The study has some limitations. Firstly, it is based on a quite small number of appraisals. This did  
18 not allow to analyze possible different patterns of association between the three innovativeness  
19 criteria and the type of innovativeness (i.e., fully or conditionally innovative). Only the availability  
20 of a larger number of innovativeness appraisals will allow to address this issue.

21  
22 As already mentioned, innovativeness appraisals can be requested by the companies or  
23 spontaneously carried out by AIFA. The information on the applicant was not available and no  
24 stratified analysis could be performed, despite it would have been very interesting. We could analyze  
25 only the final appraisal published by AIFA, but we did not have any access to the applications  
26 submitted by the companies. This implies that the results of the present study cannot be considered a  
27 predictor of the response by AIFA to the applicant. However, our analysis was aimed at evaluation of  
28 the key drivers and the consistency of the AIFA decision-making process, rather than the comparison  
29 of applications submitted by the companies and final decision of AIFA.

1  
2  
3 Despite the above-mentioned limitations, our analysis has some important implications. Companies  
4 are pushed to provide solutions with an added therapeutic value and a high quality of evidence, since  
5 the latter are the driver of innovativeness, which brings important advantages for market access. We  
6 are aware that investments by the pharmaceutical companies are taken globally, but the more HTA  
7 agencies insist on clear and transparent criteria to appraise new medicines, the higher will be the  
8 impact on the management of pipelines by the pharmaceutical companies.  
9

10  
11 The new process implemented by AIFA is also consistent with the need to rely on a pre-specified  
12 value framework enhancing transparency, accountability and, because of its intrinsic consistency,  
13 predictability of innovativeness appraisals.  
14

15  
16 Last but not least, prioritization of access through innovativeness is managed transparently, on the  
17 grounds of quite objective criteria and providing the whole stakeholders with the rationale of  
18 decision taken.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

## 38 **CONCLUSION**

39  
40  
41 To date, the new Italian innovativeness appraisal framework looked generally coherent and can be  
42 considered an important step towards a more transparent and evidence-based management of access  
43 to medicines in Italy. In the future, the process could be further enhanced, for example including in a  
44 more structured framework patients reported outcome measures, which role is still debated, whereas  
45 at present the appraisal process mostly relies on clinical variables, and proving for an interaction  
46 between innovativeness (and its domains) appraisals and price negotiation.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Contributors:** CG, PB and CJ designed the study and developed the methods. CG and PB reviewed  
4 the literature. CG, PB and CJ contributed to the data analysis and interpretation. CG prepared the  
5 tables. CG and CJ drafted the manuscript. PB provided critical review of the manuscript. All authors  
6 have reviewed and approved the final version of the manuscript for publication.  
7  
8  
9  
10  
11  
12  
13  
14  
15

16 **Competing interests:** This research was partially funded by a grant from Celgene to Statinfo. CG is  
17 a senior consultant at Statinfo. CJ and PB have received a consultant fee from Celgene as scientific  
18 consultants for the project. Celgene was not involved in the preparation, drafting or editing of this  
19 manuscript.  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 **Data Statement:** Data are available in a public, open access repository. Appraisal reports on  
30 innovativeness are publicly downloadable from the AIFA's website at  
31 <https://www.aifa.gov.it/farmaci-innovativi>.  
32  
33  
34  
35  
36  
37  
38

39 **Funding:** This research was partially funded by a grant from Celgene to Statinfo.  
40  
41

42 **Acknowledgement:** The authors thank L. Benedan for her editorial assistance and M. Iannantuoni  
43 for providing graphic design assistance.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Panteli D, Arickx F, Cleemput I, *et al.* Pharmaceutical regulation in 15 European countries. Review. *Heal Syst Transit* 2016;**18**:1–122.
- 2 Jommi C, Minghetti P. Pharmaceutical pricing policies in Italy. In: Babar Z-U-D, ed. *Pharmaceutical Prices in the 21st Century*. Adis, Cham: Springer 2015. 131–50. doi:10.1007/978-3-319-12169-7\_8
- 3 AIFA. Criteri per la classificazione dei farmaci innovativi e dei farmaci oncologici innovativi ai sensi dell'articolo 1, comma 402, della legge 11 dicembre 2016, n. 232. 2017; 519.
- 4 Atkins D, Best D, Briss PA, *et al.* Grading quality of evidence and strength of recommendations. *BMJ* 2004;**328**:1490. doi:10.1136/bmj.328.7454.1490
- 5 Fortinguerra F, Tafuri G, Trotta F, *et al.* Using GRADE methodology to assess innovation of new medicinal products in Italy. *Br J Clin Pharmacol* 2019;**86**:93–105. doi:10.1111/bcp.14138
- 6 Scavone C, Capuano A, Rossi F. New criteria of Italian Medicine Agency for the attribution of therapeutic innovation: viewpoint of the pharmacologist. *G Ital di Farm e Farm* 2017;**9**:5–12.
- 7 Urbinati D, Rova A, Cioni L. The impact of the new innovative algorithm in Italy. *Value Heal* 2018;**21**:S164. doi:10.1016/j.jval.2018.09.977
- 8 Sligh S. Italy's new pharmaceutical innovation ranking system: key criteria for successfully achieving innovative status. *Value Heal* 2018;**21**:S196. doi:10.1016/j.jval.2018.09.1168
- 9 Meremetidis A, Ferrario M, Giuliani G. The new AIFA innovation framework to recognize innovative drugs: a preliminary analysis of key drivers of evaluation. *Value Heal* 2018;**21**:S160. doi:10.1016/j.jval.2018.09.955



- 1  
2  
3 10 Di Marzio S. E l'AIFA tracciò la strada dell'innovatività. *AboutPharma* 2017;**148**:28–30.  
4  
5  
6 11 Agenzia Italiana del Farmaco. Farmaci innovativi.  
7  
8  
9 12 The GRADE Working Group. *GRADE Handbook. Handbook for grading the quality of*  
10  
11 *evidence and the strength of recommendations using the GRADE approach*. 2013.  
12  
13  
14 13 Vreman RA, Heikkinen I, Schuurman A, *et al*. Unmet Medical Need: an introduction to  
15  
16 definitions and stakeholder perceptions. *Value Heal* 2019;**22**:1275–82.  
17  
18 doi:10.1016/j.jval.2019.07.007  
19  
20  
21  
22 14 Towse A, Barnsley P. Approaches to identifying, measuring, and aggregating elements of  
23  
24 value. *Int J Technol Assess Health Care* 2013;**29**:360–4. doi:10.1017/S0266462313000524  
25  
26  
27 15 Cherny NI, de Vries EGE, Dafni U, *et al*. Comparative assessment of clinical benefit using the  
28  
29 ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO Value Framework Net  
30  
31 Health Benefit score. *J Clin Oncol* 2019;**37**:336–49. doi:10.1200/JCO.18.00729  
32  
33  
34  
35 16 Grössmann N, Del Paggio JC, Wolf S, *et al*. Five years of EMA-approved systemic cancer  
36  
37 therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit.  
38  
39 *Eur J Cancer* 2017;**82**:66–71. doi:10.1016/j.ejca.2017.05.029  
40  
41  
42  
43 17 Jommi C, Armeni P, Costa F, *et al*. Implementation of value-based pricing for medicines. *Clin*  
44  
45 *Ther* 2020;**42**:15–24. doi:10.1016/j.clinthera.2019.11.006  
46  
47  
48 18 Sussex J, Towse A, Devlin N. Operationalizing value-based pricing of medicines: a taxonomy  
49  
50 of approaches. *Pharmacoeconomics* 2013;**31**:1–10. doi:10.1007/s40273-012-0001-x  
51  
52  
53 19 Ruof J, Schwartz FW, Schulenburg J-M, *et al*. Early benefit assessment (EBA) in Germany:  
54  
55 analysing decisions 18 months after introducing the new AMNOG legislation. *Eur J Heal*  
56  
57 *Econ* 2014;**15**:577–89.  
58  
59  
60

- 1  
2  
3 20 Drummond M, de Pouvourville G, Jones E, *et al.* A comparative analysis of two contrasting  
4 European approaches for rewarding the value added by drugs for cancer: England versus  
5 France. *Pharmacoeconomics* 2014;**32**:509–20.  
6  
7  
8  
9  
10  
11 21 Li J, Vivot A, Alter L, *et al.* Appraisal of cancer drugs: a comparison of the French health  
12 technology assessment with value frameworks of two oncology societies. *Expert Rev*  
13 *Pharmacoecon Outcomes Res* 2019;**26**:1–5.  
14  
15  
16  
17  
18 22 Theidel U, von der Schulenburg JMG. Benefit assessment in Germany: implications for price  
19 discounts. *Health Econ Rev* 2016;**6**:1–12. doi:10.1186/s13561-016-0109-3  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure Legend**  
4  
5  
6

7 Figure 1 – Criteria used to evaluate innovativeness adopted by the Italian Medicines Agency.  
8 Adapted from Recchia, 2017  
9

10  
11  
12 Figure 2 – Innovative appraisals by the Italian Medicines Agency (2017-2020)  
13  
14

15  
16 Supplementary Figure 1 - Deterministic decision tree based on the available innovativeness  
17 appraisals released by the Italian Medicines Agency (2017-2020)  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Criteria used to evaluate innovativeness adopted by Italian Medicines Agency.

Adapted from Recchia, 2017

\* For rare disease there is the following exception: the fully innovative is attributed in the presence of at least important unmet therapeutic need and added therapeutic value in presence of at least low quality of clinical evidence.

\*\* The innovativeness appraisal has to be decided on a case by case basis.

494x333mm (300 x 300 DPI)




Figure 2. Innovative appraisals by the Italian Medicines Agency (2017-2020)

494x361mm (300 x 300 DPI)

Supplementary Table 1 – Description of medicine innovative appraisal, ordered by date of publication on AIFA's website – Last access 31 July 2020

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
1	daratumumab	H	Adult	Yes	July 2017	Not innovative	Important	Moderate	Low	<i>Although multiple myeloma is a rare disease (prevalence does not exceed 5 / 10,000) AIFA evaluated this medicine in a setting of non-rare disease</i>
2	glecaprevir and pibrentasvir	Non-Onco	Adult	No	July 2017	Fully innovative	Important	Important	Moderate	
3	obeticholic acid	Non-Onco	Adult	Yes	May 2017	Not innovative	Maximum	Poor	Low	
4	baricitinib	Non-Onco	Adult	No	June 2017	Not innovative	Moderate	Poor	High	
5	nusinersen	Non-Onco	Pediatric	Yes	July 2017	Fully innovative	Maximum	Important	Low	
6	palbociclib	S	Adult	No	June 2017	Not innovative	Important	Poor	Moderate	
7	palbociclib	S	Adult	No	June 2017	Conditionally innovative	Moderate	Moderate	Moderate	
8	cenegermin	Non-Onco	Adult	Yes	November 2017	Fully innovative	Important	Important	Low	
9	ceftazidime / avibactam	Non-Onco	Adult	No	July 2017	Not innovative	Important	Poor	Low	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
10	nivolumab	S	Adult	No	September 2017	Not innovative	Important	N/A	Low	<i>The added therapeutic value in this indication was considered not assessable</i>
11	allogeneic t cells genetically modified	H	Adult	Yes	September 2017	Not innovative	Moderate	Moderate	Very low	
12	daratumumab	H	Adult	Yes	October 2017	Fully innovative	Moderate	Important	Moderate	
13	sofosbuvir/velpatasvir/voxilaprevir	Non-Onco	Adult	No	July 2017	Fully innovative	Important	Important	Moderate	
14	adalimumab	Non-Onco	Adult	Yes	November 2017	Conditionally innovative	Important	Moderate	Moderate	
15	lenalidomide	H	Adult	Yes	September 2017	Conditionally innovative	Moderate	Moderate	Moderate	
16	inotuzumab ozagamicin	H	Adult	Yes	October 2017	Conditionally innovative	Moderate	Moderate	Moderate	
17	atezolizumab	S	Adult	No	November 2017	Fully innovative	Important	Moderate	High	
18	bezlotoxumab	Non-Onco	Adult	No	October 2017	Not innovative	Important	Moderate	Low	
19	dinutuximab beta	S	Mixed	Yes	February 2018	Fully innovative	Maximum	Important	Moderate	
20	dinutuximab beta	S	Mixed	Yes	February 2018	Not innovative	Maximum	Important	Very low	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
21	alectinib	S	Adult	No	January 2018	Conditionally innovative	Moderate	Moderate	Moderate	
22	alectinib	S	Adult	No	January 2018	Fully innovative	Moderate	Important	Moderate	
23	nivolumab	S	Adult	No	November 2017	Conditionally innovative	Important	Moderate	Moderate	
24	midostaurin	H	Adult	Yes	December 2017	Fully innovative	Moderate	Important	Moderate	
25	midostaurin	H	Adult	Yes	December 2017	Not innovative	Important	Poor	Low	
26	ibrutinib	H	Adult	Yes	October 2017	Conditionally innovative	Moderate	Moderate	Moderate	
27	dupilumab	Non-Onco	Adult	No	January 2018	Fully innovative	Important	Moderate	High	
28	ocrelizumab	Non-Onco	Adult	No	February 2018	Not innovative	Maximum	Poor	Moderate	
29	letemovir	Non-Onco	Adult	Yes	February 2018	Fully innovative	Moderate	Important	High	
30	avelumab	S	Adult	Yes	January 2018	Conditionally innovative	Important	Moderate	Low	
31	canakinumab	Non-Onco	Mixed	Yes	December 2017	Conditionally innovative	Important	Moderate	Moderate	
32	ibrutinib	H	Adult	Yes	July 2017	Not innovative	Poor	Poor	Moderate	
33	ribociclib	S	Adult	No	November 2017	Conditionally innovative	Moderate	Moderate	Moderate	
34	nivolumab	H	Adult	Yes	July 2017	Conditionally innovative	Maximum	Moderate	Low	



ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
35	niraparib	S	Adult	Yes	January 2018	Conditionally innovative	Important	Moderate	Moderate	
36	regorafenib	S	Adult	No	February 2018	Conditionally innovative	Maximum	Moderate	High	
37	emicizumab	Non-Onco	Mixed	Yes	June 2018	Fully innovative	Moderate	Important	Low	
38	ethyl telotristat	S	Adult	Yes	January 2018	Not innovative	Important	Poor	Moderate	
39	liposomal daunorubicin hydrochloride / cytarabine	H	Adult	Yes	November 2018	Fully innovative	Moderate	Important	Moderate	
40	pembrolizumab	S	Adult	No	May 2019	Fully innovative	Moderate	Important	High	
41	tocilizumab	Non-Onco	Adult	Yes	July 2018	Conditionally innovative	Moderate	Moderate	Moderate	
42	daratumumab	H	Adult	Yes	October 2017	Fully innovative	Moderate	Important	Moderate	
43	cladribine	Non-Onco	Adult	No	April 2018	Not innovative	Moderate	Poor	Very low	
44	lutetium oxodotreotide	S	Adult	Yes	March 2018	Fully innovative	Important	Important	Low	
45	darvadstrocel	Non-Onco	Adult	Yes	April 2019	Not innovative	Moderate	Poor	Low	
46	cysteamine	Non-Onco	Mixed	Yes	January 2018	Not innovative	Poor	Moderate	Very low	
47	obinutuzumab	H	Adult	Yes	March 2018	Not innovative	Poor	Poor	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
48	pembrolizumab	S	Adult	No	June 2018	Conditionally innovative	Important	Moderate	High	
49	pembrolizumab	H	Adult	Yes	November 2017	Conditionally innovative	Maximum	Moderate	Low	
50	pertuzumab	S	Adult	No	November 2018	Not innovative	Moderate	Poor	Moderate	
51	tisagenlecleucel	H	Mixed	Yes	January 2019	Fully innovative	Important	Important	Moderate	
52	tisagenlecleucel	H	Adult	Yes	January 2019	Fully innovative	Important	Important	Low	
53	burosumab	Non-Onco	Pediatric	Yes	December 2018	Conditionally innovative	Important	Moderate	Low	
54	durvalumab	S	Adult	No	March 2019	Fully innovative	Important	Important	Moderate	
55	lenvatinib	S	Adult	Yes	April 2019	Not innovative	Important	Absent	Moderate	
56	brentuximab vedotin	H	Adult	Yes	April 2018	Conditionally innovative	Moderate	Moderate	Moderate	
57	pembrolizumab	S	Adult	No	May 2019	Fully innovative	Important	Moderate	High	
58	pembrolizumab	S	Adult	No	May 2019	Fully innovative	Moderate	Important	Moderate	
59	nivolumab	S	Adult	No	April 2019	Fully innovative	Important	Moderate	High	
60	osimertinib	S	Adult	No	February 2019	Fully innovative	Moderate	Important	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
61	acicabtagene ciloleucel	H	Adult	Yes	January 2019	Fully innovative	Important	Important	Moderate	
62	dabrafenib	S	Adult	No	April 2019	Fully innovative	Important	Important	High	
63	trametinib	S	Adult	No	April 2019	Fully innovative	Important	Important	High	
64	doravirina/ lamivudina/ tenofovir disoproxil	Non-Onco	Adult	No	May 2019	Not innovative	Poor	Poor	Moderate	
65	doravirine	Non-Onco	Adult	No	May 2019	Not innovative	Poor	Poor	Moderate	
66	venetoclax	H	Adult	Yes	April 2019	Conditionally innovative	Moderate	Moderate	Moderate	
67	abemaciclib	S	Adult	No	May 2019	Conditionally innovative	Moderate	Moderate	Moderate	
68	caplacizumab	Non-Onco	Adult	Yes	February 2019	Conditionally innovative	Moderate	Moderate	Low	
69	patisiran	Non-Onco	Adult	Yes	November 2018	Fully innovative	Important	Important	Moderate	
70	emicizumab	Non-Onco	Mixed	Yes	October 2019	Conditionally innovative	Moderate	Moderate	Low	
71	metreleptin	Non-Onco	Mixed	Yes	February 2019	Conditionally innovative	Maximum	Moderate	Very low	<i>Ultra-rare disease</i>
72	abiraterone acetate	S	Adult	No	May 2018	Not innovative	Moderate	Poor	Moderate	
73	alirocumab	Non-Onco	Adult	No	November 2019	Not innovative	Moderate	Poor	Moderate	

ID	Medicine	Disease Group	Population	Rare disease*	CTS date	Innovation status	Unmet need	Added value	Quality of evidence	Notes
74	encorafenib	S	Adult	No	May 2019	Not innovative	Moderate	Poor	Moderate	
75	binimetinib	S	Adult	No	May 2019	Not innovative	Moderate	Poor	Moderate	
76	lanadelumab	Non-Onco	Mixed	Yes	December 2019	Not innovative	Moderate	Poor	Moderate	
77	cerliponase alfa	Non-Onco	Pediatric	Yes	December 2018	Fully innovative	Maximum	Important	Very low	Ultra-rare disease

\* according to orphanet

AIFA: italian medicines agency; CTS: techical-scientific commitee; H: hematological malignancies; S: solid tumor; onco: oncological disease; non-onco: non oncological disease

For peer review only

Supplementary Figure 1. Deterministic decision tree based on the available innovativeness appraisals released by the Italian Medicines Agency (2017-2020)

